

OHE



OHE Annual
Report to the
Charity
Commission
for the year 2019

RESEARCH REPORT
SEPTEMBER 2020

Mireia Jofre-Bonet
Office of Health Economics, London

SEPTEMBER 2020

OHE Annual Report to the Charity Commission for the year 2019

Mireia Jofre-Bonet

Office of Health Economics, London

Graham Cookson

Office of Health Economics, London

Please cite this report as:

OHE, 2020. OHE Annual Report to the *Charity Commission for the year 2019*, London: Office of Health Economics. Available at: <https://www.ohe.org/publications/> (TBC)

Corresponding Author:

Mireia Jofre-Bonet

mjofre-bonet@ohe.org

For further information please contact:

Professor Graham Cookson

Chief Executive, OHE

Honorary Visiting Professor in Economics at City, University of London

Tel +44 (0)207 747 1408

Email gcookson@ohe.org

Table of Contents

About OHE.....	iii
1 Our Year in Numbers	4
2 Administrative information	5
3 Introduction	2
4 Activities Undertaken in 2019 in fulfilment of our charitable objects.....	3
5 Financial review	5
6 Plans for 2020.....	7
7 Structure, governance, and management in 2019	7

About OHE

OHE'S MISSION STATEMENT

Support better health care policies by providing insightful economic and statistical analyses of critical issues

HOW WE ARE ORGANISED

OHE is a charity with registered charity number 1170829. OHE is managed by a senior management team. Its governance is the responsibility of its Board of Trustees. In 2017 the Board of Trustees had three sub-committees with advisory roles: a Research and Policy Committee, which provided advice and guidance to OHE on its research programme; an Editorial Committee, which reviewed OHE's in-house publications, ensuring their intellectual rigour and value; and a Management Committee, which assisted OHE with its operational and business planning.

The ultimate parent undertaking and controlling party of the company is The Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales 09826787, by virtue of it being the sole member of the company.

OHE's consulting work is carried out by OHE Consulting Limited, a for-profit company with registered company number 09853113. OHE Consulting Limited is wholly owned by The Office of Health Economics. For consulting projects, the client has a proprietary right to any intellectual property arising from the work, distinct from research projects where OHE retains the intellectual property

WHO WE ARE, HOW AND WHERE WE WORK

By the end of 2019 the OHE team comprised 1 CEO, one Vice-President Head of Consulting; one Vice-President Head of Research, one Emeritus Director & Senior Research Fellow; one Director, two Associate Directors; four Principal Economists, six Senior Economists, one Business Intelligence Specialist, four Economists, and three Administrative Support staff. Also, in 2019 OHE had seven Honorary Research Fellows.

We emphasise projects that tackle impactful policy and strategic issues with current and future significance. Our work involves stakeholders, clients, and external experts in order to obtain crucial new policy insights, identify strategies and optimal choices.


Although OHE is based in London, we undertake projects both in the UK and internationally. We work collaboratively with a wide network of academics and other partners across the world.

HOW WE ARE FUNDED

OHE's work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources. OHE receives an annual research grant from the Association of the British Pharmaceutical Industry (ABPI) and undertakes consulting work for ABPI and other commercial clients, surplus from which is used to self-fund research projects identified as priorities.

Our research programme is also funded by grants obtained from UK research councils and other national and international research funders, including the National Institute for Health Research (NIHR), the Health Foundation, the Cancer Research UK, the EuroQol Research Foundation, and a number of charitable and other organisations.

1 Our Year in Numbers



2 Administrative information

Trustees and Directors

M Thompson Trustee
 B Jönsson Trustee
 M Drummond Trustee
 H Ahmad Trustee
 C Fox Trustee
 L. Timlin Trustee
 A Charlesworth Trustee

Registered Office

7th Floor, Southside
 105 Victoria Street
 London SW1E 6QT

Charity number: 1170829
Company number: 09848965

Auditor

BDO LLP
 Statutory Auditor & Chartered Accountants
 2 City Place
 Beehive Ring Road
 Gatwick
 West Sussex RH6 0PA

Bankers

National Westminster Bank Plc
 PO Box 113
 Cavell House
 2A Charing Cross Road
 London

Senior Management

Chief Executive Officer

Prof Graham Cookson

Head of Research and Vice President

Prof Mireia Jofre-Bonet

Head of Consultancy and Vice President

Prof Lotte Steuten

Director:

Martina Garau

Associate Directors:

Grace Hampson

Chris Skedgel

3 Introduction

This is the third report to the Charity Commission for England and Wales since becoming a registered charity in December 2016.

This year, we have changed the format of this report to avoid the overlap of previous Charity Reports with the research reports that we produce each year for OHE's **Research Committee** and for the **Board of Trustees**. This year's **Charity Report for 2019** includes the current document in which we highlight some of our work and the required financial information. The report is complemented by the **Research Summary of 2019 for the Charity Report** which provides our research activity for 2019 in detail, based on the report submitted to the Research Committee in January of 2020.

As in the two previous years, the **Charity Report for 2019** shows that OHE has kept its commitment to its charitable objects of *advancing the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy; and using health economics methods to produce evidence-based health policy and health care management that contributes to a more efficient and effective health care system.*

Beyond OHE's charitable objects at OHE we also support:

- the advancement of evidence-based health care policy by engaging in research on the economics of health, health care systems and the life sciences industry;
- research for the effective and efficient use of health care resources, by advancing the use of economic approaches to support decision making; and
- decision making and awareness of health care policy issues by promoting debate and dissemination of relevant health economics research.¹

Partly because OHE's commitment to its charitable objects, as we write this report OHE has been awarded **Independent Research Organisation** status (in February 2020). This is granted by UK Research and Innovation (UKRI) which – through the seven Research Councils, Innovate UK and Research England – allocates more than £7 billion in research funding, primarily from the Science Budget of the Department for Business, Energy and Industrial Strategy (BEIS). IRO status is a recognition of OHE's high quality of independent research, and places us on equal footing with the UK's Higher Education Institutions, making us eligible to apply for UKRI funding on the same terms to better fulfil our charitable aims.

In obtaining IRO status, OHE joined a highly selective list of organisations conducting research in health economics (and related areas), namely: the Institute for Fiscal Studies (IFS); the National Centre for Social Research (NatCen); the National Institute of Economic and Social Research (NIESR); Nesta; the Overseas Development Institute (ODI); Rand Europe; and the Wellcome Trust Sanger Institute. Across the UK, there are only 63 IROs in total across all research fields, including areas as diverse as medicine, defence studies, history, and oceanography.

¹ As in the two previous reports, the term *health economics* shall mean the application of economic theory, models and empirical techniques to the analysis of decision making by people, health care providers and governments with respect to health and health care

4 Activities Undertaken in 2019 in fulfilment of our charitable objects

In this section, we highlight examples of how OHE fulfilled charitable objects in 2019. A more detailed account of our activity is contained in the attached **Research Summary of 2019 for Charity the Report 2020**. The report covers all OHE's research activities undertaken during the aforementioned year, i.e., all articles published in peer-reviewed journals, OHE peer-reviewed articles, consultancy reports, blogs on salient health economics issues and relevant events. It also highlights selected examples of our work for their impact and citations as well as conferences attended by OHE staff, presentations at other fora, research collaborations, OHE's lunch time seminar series, brown bag seminars and a summary of the 2019 OHE Annual Lecture. Finally, the report lists the honorary positions other pro-bono activities that OHE staff hold in line with OHE's charitable objects. As in 2018, the research summary demonstrates that OHE's research promotes the effective and efficient use of health care resources by improving the application of economic methodology to sustain health care decision making.

The charitable object of *using health economics methods to produce evidence-based health policy and health care management that contributes to a more efficient and effective health care system* is mostly accomplished through research activities. These include articles that emerge from a research project and/or are originally supported by our core grant and then become a peer-reviewed article or OHE publication, and workshops we organised that involve health care system stakeholders with different perspectives, so that they can learn of our research and its health policy implications..

The charity object of *advancing the education of the public in general/health care payers/policy makers on the subject of health economics and health care policy* is mostly fulfilled through our dissemination activities beyond publications, including the broadcasting of our findings in more general fora, thereby educating and informing health care decision makers, patients and the general public.

The **Research Summary of 2019 for Charity Report 2020** contains numerous examples of work that had a theoretical and/or practical impact and thus contributed to the knowledge transfer of health economics and on how to improve the health and wellbeing of the population. Here, we have selected the following pieces of work as examples of research that has resonated in the health policy debate and have helped spread knowledge in health economics.

- The paper **HTA and Payment Mechanisms for New Drugs to Tackle AMR** appeared as a peer-reviewed article on the OHE website and was widely cited, including by *NHS networks* and the *Kings Fund*. The paper provides an overview of the state of HTA and contracting for antibiotics in five European countries, and of the recent proposals in the literature for revising them. It also includes the recommendations developed following a stakeholder Forum on 'Value Assessment and Contracting for Antibiotics' held in February 2019. This is a topic the importance of which has been intensified by the COVID-19 pandemic and the consequent discussion on the pros and cons of pull and push mechanisms to incentivise R&D in specific areas of life sciences. This is a typical example of a piece of OHE work contributing to the research debate on a very topical subject and ultimately, directly, or indirectly, informing health policy.

- The study **Unrelieved Pain in Palliative Care in England** estimated that there were approximately 125,971 end-of-life patients receiving, or in need of, palliative care suffering from unrelieved pain. Of these, about 16,130 patients experienced no relief from their pain at all in the last three months of life. Some of these patients suffered unnecessarily because of variations in the quality of care across care settings. The paper was again widely cited and was included as written evidence submitted by *Dignity in Dying* in a *UK Parliament Committee* hearing.
- An example of a core funded project that develops from a OHE report to become an influential paper published in a good peer-reviewed journal is **Public Sector Opportunity Cost Developing**. The paper was built on a working paper resulting from the *Public Sector and Opportunity Cost project* funded as a research project by ABPI.
- Another example of the core research grant aiding to disseminate OHE research is that of the paper **R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C**. This article analyses the functioning of a specific market for innovative treatments, Direct Acting Antivirals (DAAs) for hepatitis C virus (HCV) in six European countries. The authors explore potential for in-class competition for DAAs to 1. offset innovators' market power and, 2. to maximise the social welfare generated by the adoption of pharmaceutical innovation via lower prices. The paper is now being submitted to a peer-reviewed prestigious journal thanks by the core research funding.
- In February 2019, the OHE Research Paper **Making Outcome-Based Payment a Reality in the NHS** was published online. The report was the result of a research grant awarded to The Office of Health Economics and RAND Europe in collaboration with King's College London in 2018 by Cancer Research UK and Greater Manchester Health and Social Care Partnership (GMHSCP). This first phase of the project explored what outcomes patients with cancer value most which might form a practical basis for outcome-based payment. In October 2019 OHE, in collaboration with RAND Europe, University College London (UCL), and The University of Manchester (UoM), was awarded a research grant from Cancer Research UK in partnership with Greater Manchester Health & Social Care Partnership (GMHSCP), funding the second phase of the 'Making Outcome-Based Payment a Reality in the NHS' programme of work. The report was cited in a press release by Cancer Research UK. It was also cited by commentators and media outlets such as Pharmatimes, Pharmafield, PMLive, The Pharma Letter, Royal College of Nursing, Health Innovation Manchester, Centre for Health and the Public Interest, EI Global, InVivo - Informa Pharma Intelligence, and Medscape. The Medscape article included a quote from NICE welcoming the publication of the paper.
- **Pro bono activities:** The attached research summary for 2019 shows that OHE staff have been engaged in a wide variety of *pro bono* activities, including ten visiting positions at Universities and prestigious think-tanks, participation on advisory boards, serving on committees, supervising student placements, examining doctoral research theses, and undertaking reviews.
- **Other research and dissemination outputs:** In terms of outputs, OHE staff produced 24 external publications (16 of which were peer-reviewed), 5 lunchtime seminars, 1 Annual Lecture, 74 external presentations, 10 brown bag presentations and 56 blogs.
- **Research awards from prestigious funders:** As a demonstration of OHE reputation and independence, it is worth noting that in 2019, OHE was awarded three research grants by prestigious funders, i.e. *Cancer Research UK, Health Foundation, EuroQol Research Foundation*. These three research grants, along with other research projects, amounted to a value of £0.58m.

5 Financial review

5.1 OHE's financial structure

In 2019, OHE remained an organisation that undertakes research and related activity in line with its charitable objectives.

As reported last year, OHE owns the sole share in OHE Consulting Limited with the purpose of:

- Enabling OHE to employ a larger staff team than would be possible using research income alone.
- Allowing staff gain knowledge, skills and experience undertaking consulting projects that can be carried across into research and research-related projects.
- Investing the profits generated from consultancy work as Gift Aided to OHE, subject to the agreement of the Directors of OHE Consulting Limited. This continued to be an important source of income for OHE in 2019.

During 2019, OHE employed an average of 26 staff.

5.2 OHE's financial performance in 2019

The financial statements of OHE comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) ("Charities SORP FRS 102").

OHE's consolidated turnover (i.e. combining both OHE and OHE Consulting Limited) in 2019 was **£3.71m**. The expenditure totalled **£3.45m** which left a net income of **£264,176**, larger than that of 2018.

Of the £3.71m expenditure, staff costs in 2019 amounted to **£2.08m**, i.e. 56%.

Support services for the consolidated businesses accounted for **£0.30m**.

The consolidated accounts for OHE are included as an Annex to this report.

5.3 Sources of funding

The sources of funding of OHE are summarised below. More detail about OHE income and expenditure are provided in the financial reports, attached.

The consolidated income of £3.03m comprises:	£000
Donations – research grants	714.66
Income from charitable (research) activities	643.08
Interest	1.05
Total research income	1,358.79
OHE Consulting Income	2,360.98
Total Income	3,719.78

Donations are from the ABPI and are for two distinct purposes:	£000
Support for core research activities	350.00
Grant towards financing of support activities	364.66
Total	714,66

Income from charitable (research) activities came from a number of sources. Major research projects and funders included:

- Cancer Research UK
- Health Foundation, the Cancer Research UK
- EuroQol Research Foundation

6 Plans for 2020

The plans for 2020 are summarised in the **Research Summary of 2019 for the Charity Report 2020**, but we will highlight here the most ambitious ones:

1. Organise a **OHE Annual Conference** from September 2020.
 - *Note:* although we were ready to launch it, COVID-19 forced us to postpone the conference until 2021.
2. Increase the number and areas of expertise of **OHE Visiting Fellows** and deepen these and existing relationships.
3. **Enhance the training opportunities and programmes:**
 - Start a OHE MSc in Health Economics Fellowship at City, which began effectively in September 2020.
 - Explore the possibility of finding partners for a PhD in the Micro-economics and Econometrics of the Pharmaceutical Industry.

In 2020, we aimed to systematise and promote further our research activity by organising quarterly meetings for each of our four research themes, develop a method to filter funding calls of interest to OHE, and improve direct access to Digital Libraries. Further, we were planning to organise a **lunch-time journal club** but this latter project was stalled by the disruption caused by COVID-19.

In terms of promotion and guidance for OHE's research activity, we also planned - and have successfully executed - the creation of a standalone **Research Committee** which continues to include highly regarded academics. Its remit is to advise OHE on research-related issues, separately from policy and impact related matters, for which we introduced a **Policy Committee**.

7 Structure, governance, and management in 2019

During 2019, the structure of OHE changed quite dramatically, as depicted in Figures 1 and 2 below.

The new structure in Figure 2 reflects how by the end of 2019 OHE moved on to dis-establish the **Research and Policy Committee** and to create a **Research Committee** as separate committee from the **Policy Committee**.

The purpose of creating a **Policy Committee** is to provide advice to OHE on engaging with policymaking and to ensure that OHE meets its Charitable Objects in this respect. OHE's work has been informing health care and pharmaceutical decision-makers as well as health care payers for decades, building its reputation on producing independent, academically strong research.

The **Research Committee**, instead, is to provide OHE with guidance on research and methods, oversee the research programme from the core research grant, ensure the quality and independence of OHE's research programme, and assure the OHE Research Board of Directors that OHE's research output is meeting its charitable objectives and purpose.

Figure 1: Organigram by the end of 2018





Figure 2: Organigram by the end of 2019



List of acronyms

ABPI	Association of the British Pharmaceutical Industry	NICE	National Institute for Health and Care Excellence
CART	Chimeric Antigen Receptor T-Cell	NIHR	National Institute for Health Research
CEO	Chief Executive Officer	OHE	Office of Health Economics
CQUIN	Commissioning for Quality and Innovation	PI	Principal Investigator
DOI	Digital Object Identifier	PRO	Patient-Reported Outcome
DIF	Differential Item Functioning	PROM	Patient-Reported Outcome Measure
EQ-5D	EuroQol Five-Dimension	QALY	Quality-Adjusted Life Year
EQ-5D-3L	EuroQol Five-Dimension Three-Level	REF	Research Excellence Framework
EQ-5D-5L	EuroQol Five-Dimension Five-Level	SPSS	Statistical Package for the Social Sciences
EQ-5D-Y	EuroQol Five-Dimension Youth	SAS	Statistical Analysis System
EU	European Union	TTO	Time Trade-Off
FDA	Food and Drug Administration	UK	United Kingdom (of Great Britain and Northern Ireland)
FTE	Full-Time Equivalent	US	United States (of America)
GDP	Gross Domestic Product		
HESG	Health Economists' Study Group		
HEHTA	Health Economics and Health Technology Assessment (University of Glasgow)		
HTA	Health Technology Assessment		
HTAi	Health Technology Assessment International		
ICER	Institute for Clinical and Economic Review [can also denote Incremental Cost-Effectiveness Ratio]		
ISPOR	International Society for Pharmacoeconomics and Outcomes Research		
MCDA	Multi-Criteria Decision Analysis		
MGHA	Melbourne Genomics Health Alliance		
MID	Minimally Important Difference		
MRC	Medical Research Council		
NHS	National Health Service		



About us

Founded in 1962 by the Association of the British Pharmaceutical Society, the Office of Health Economics (OHE) is not only the world's oldest health economics research group, but also one of the most prestigious and influential.

OHE provides market-leading insights and in-depth analyses into health economics & health policy. Our pioneering work informs health care and pharmaceutical decision-making across the globe, enabling clients to think differently and to find alternative solutions to the industry's most complex problems.

Our mission is to guide and inform the healthcare industry through today's era of unprecedented change and evolution. We are dedicated to helping policy makers and the pharmaceutical industry make better decisions that ultimately benefit patients, the industry and society as a whole.

OHE. For better healthcare decisions.

Areas of expertise

- Evaluation of health care policy
- The economics of health care systems
- Health technology assessment (HTA) methodology and approaches
- HTA's impact on decision making, health care spending and the delivery of care
- Pricing and reimbursement for biologics and pharmaceuticals, including value-based pricing, risk sharing and biosimilars market competition
- The costs of treating, or failing to treat, specific diseases and conditions
- Drivers of, and incentives for, the uptake of pharmaceuticals and prescription medicines
- Competition and incentives for improving the quality and efficiency of health care
- Incentives, disincentives, regulation and the costs of R&D for pharmaceuticals and innovation in medicine
- Capturing preferences using patient-reported outcomes measures (PROMs) and time trade-off (TTO) methodology
- Roles of the private and charity sectors in health care and research
- Health and health care statistics

Registered number: 09848965
Charity number: 1170829

THE OFFICE OF HEALTH ECONOMICS
(A company limited by guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the company, its trustees and advisers	1
Trustees' report	2 - 6
Independent auditors' report	7 - 9
Consolidated statement of financial activities	10
Consolidated balance sheet	11
Company balance sheet	12
Consolidated statement of cash flows	13
Notes to the financial statements	14 - 24

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2019**

Trustees

Ms A Charlesworth, Trustee (appointed 5 June 2019)
Ms L Timlin, Trustee (appointed 5 June 2019)
Mr P Thompson, Trustee (resigned 31 December 2019)
Mr B Jonsson, Trustee
Mr M Drummond, Trustee
Mr H Ahmad, Trustee
Ms C Fox, Trustee

Company registered number

09848965

Charity registered number

1170829

Registered office

7th Floor, Southside
105 Victoria Street
London
SW1E 6QT

Company secretary

R Hollingsworth

Independent auditors

BDO LLP
Statutory Auditor & Chartered Accountants
2 City Place
Beehive Ring Road
Gatwick
West Sussex
United Kingdom
RH6 0PA

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

The Trustees, who are also directors for the purposes of company law, present their report together with the audited consolidated financial statements of the group and the company, 'The Office of Health Economics' ("OHE", "the charitable company", "the charity" or "the company") (registered in England and Wales), and its subsidiary undertaking OHE Consulting Limited (registered in England and Wales) (collectively "the group") for year ended 31 December 2019.

The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) as amended by Update Bulletin 1 (effective 1 January 2015).

As stated in Note 17 to the financial statements the ultimate parent company of OHE is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"). The ABPI provides a research grant to OHE to enable it to independently progress its charitable purpose and objectives as summarised below.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) ("Charities SORP FRS 102").

Objectives and Activities

The Office of Health Economics' objectives are to advance the education of the public in general/health care payers/policy makers, particularly patients and healthcare professionals, on the subject of health economics and healthcare policy.

Activities in furtherance of this include, in particular, but not exclusively:

- the promotion of evidence based health care policy, by carrying out research on the economics of health, health care systems and the life sciences industry;
- the promotion of effective and efficient use of health care resources, by advancing the use of economic approaches to support decision making; and
- the facilitation of decision making and awareness of health care policy issues, by encouraging debate and dissemination of relevant health economics research.

The term "health economics" means the application of economic theory, models and empirical techniques to the analysis of decisions making by people, health care providers and governments with respect to health and health care.

In planning the activities of the charity, the Trustees have had regard to the Charity Commission's guidance on public benefit. They consider the information which follows in this annual report, about the company's aims, activities and achievements in the areas of interest that the company supports demonstrates the benefit to its beneficiaries and through them to the public.

Achievements and performance

OHE has once again undertaken an ambitious programme of original research, generating findings published in high quality peer reviewed journals, and via its own publication series, on the economics of health technology appraisal, the economics of health care systems and the economics of the life sciences industry. OHE's work has direct relevance to policy, and evidence from our research programme informs health care decision making and health care policy. OHE also contributes directly to the development and promotion of excellence in the field of health economics via our seminars, lectures, leadership roles in professional societies, and other academic

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

activities. OHE's consulting arm has produced authoritative analyses for our clients and a financial surplus from which it contributes to the financial sustainability of OHE as a research charity.

The company and group have continued to perform successfully this year. Internal and external funding has continued to be provided to finance a wide range of research projects and consultancy advice provided to the life sciences industry, public sector organisations and the ABPI.

The key performance indicators are external research funding targets, consultancy income targets and operating expenditure targets. In 2019, research funding was 81% of target and consultancy income was 113% of target. Operating expenditure in 2019 was 96% of the budget target. The resulting operating profit is an improvement year on year and has allowed the company to further build its own financial reserves, in line with the reserves policy.

Financial review

a. Going concern

After making appropriate enquiries, and getting confirmation of on-going support from ABPI (Note 17), the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

The Trustees are aware that the operational and financial implications of Covid-19 have been considered by the Governance Committee of OHE's ultimate parent company the ABPI. The Governance Committee have concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements.

b. Reserves policy

The Trustees have examined the charitable company's requirement for resources in light of the main risks to the company and have no outstanding commitments or cash demand which are not adequately covered by existing resources.

The group's reserves policy continues to ensure that the company has adequate cash and reserves to meet current and future needs, and this is reviewed annually as part of the budget process. The Trustees have agreed with the ABPI that the research grant will in principle be a fixed amount each year, to help enable OHE to record an operating profit each year and build its own financial reserves.

The policy will seek to balance the goal of sustainability with the needs to be efficient as a not for profit organisation. Research funding and consultancy contracts are always agreed before making any expenditure commitments.

c. Work programmes and funding

The company's current work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources including the ABPI and other commercial clients, the Medical Research Council ("MRC"), the EuroQoL Foundation and a number of charitable and other organisations.

d. Results for the year

OHE Consulting Limited, the company's wholly owned subsidiary, made an operating profit of £593,202 (2018 - £152,643) in 2019 and made a gift aid payment for this amount to its parent company, the OHE.

The company made an operating loss of £329,026 (2018 - £95,541) prior to the gift aid payment received from OHE Consulting Limited, and therefore overall the group realised a profit for 2019.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

e. Fundraising

Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. Although we do not undertake fundraising from the general public, the legislation defines fund raising as "soliciting or otherwise procuring money or other property for charitable purposes." Such amounts receivable would be presented in our accounts as "voluntary income" and includes legacies and grants.

Structure, governance and management

a. Constitution and legal structure

The company is registered as a charitable company limited by guarantee (charity number 1170829) and was set up by a Memorandum of Association on 29 October 2015 .

The company has a wholly owned subsidiary, OHE Consulting Limited, a company limited by shares. This company provides health economic consultancy services to the life sciences industry. The legal structure enables the research activities of the charitable company to be kept separate to the commercial consultancy activity. Both companies share the same directors and key management personnel.

b. Method of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and co-opted under the terms of the Memorandum of Association.

The ABPI, as the sole member of the charity, has the sole right to appoint Trustees to the Board of the charity.

c. Policies adopted for the induction and training of Trustees

As part of their training, Trustees are provided a comprehensive 'operating' manual, which includes the charitable company's Memorandum of Association and Charity Commission guidance on trustee responsibility. All Trustees are aware of their legal duties and obligations in respect of the management of the charitable company, including in relation to the protection of its assets.

d. Pay policy for senior staff

Three Trustees received fees for services twice during the period. Details of Trustees' fees, expenses and related party transactions are disclosed in Note 8 to the financial statements.

The company uses benchmark data from other research and consultancy organisations to help set pay and remuneration for key staff. Annual pay reviews are then linked to performance against agreed objectives, inflation rates and market trends.

e. Organisational structure and decision making

The company is governed by the Board of Trustees. The Trustees during the period were as follows:

Ms A Charlesworth, Trustee (appointed 5 June 2019)
Ms L Timlin, Trustee (appointed 5 June 2019)
Mr P Thompson, Trustee (resigned 31 December 2019)
Mr B Jonsson, Trustee
Mr M Drummond, Trustee
Mr H Ahmad, Trustee
Ms C Fox, Trustee

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

In addition to the Board of Trustees, the company is managed by the Executive Management Team, and advised by both an Editorial Committee and a Research and Policy Committee.

The Executive Management Team during the period were as follows:

Mr G Cookson (Chief Executive)
Ms L Steuten (Vice President of Consulting)
Ms M Jofre-Bonet (Vice President of Research)

f. Risk management

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to manage the exposure to the major risks.

The principal risks facing the company and group are a reduction in research funding or consultancy income together with the loss of key staff. Funding and income wins and proposals are closely monitored against budget expectations by the Executive Management Team and if necessary cost savings are identified to cover any income shortfall. A competitive remuneration package, development through work experience and succession planning are used to attract and retain high calibre staff.

Plans for future periods

OHE will continue to develop its programme of original research, supported by a wide range of research funders in the UK and internationally. OHE will continue to expand the focus of our work beyond the UK, and to focus effort on maximising the impact of our research on improving health care decision making both in the UK and further afield. In its role as a newly-established charity, OHE will be developing evidence-based policy positions, which it will advocate by engaging with a wide range of stakeholders via events, media commentaries, and publications.

Trustees' responsibilities statement

The Trustees (who are also directors of OHE for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial period. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in operation.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

**TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2019**

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company and the group's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable company and group's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company and group's auditors are aware of that information.

Auditors

The auditors, BDO LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2016 relating to small companies.

This report was approved by the Trustees, and signed on their behalf by:

Trustee

Date:

Trustee

Date:

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS

Opinion

We have audited the financial statements of The Office of Health Economics ("the parent Charitable Company") and its subsidiaries ("the Group") for the year ended 31 December 2019 which comprise the consolidated statement of financial activities, the consolidated and parent charitable company balance sheets, the consolidated cash flow statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the Group's and of the Parent Charitable Company's affairs as at 31 December 2019 and of the Group's incoming resources and application of resources for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions related to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the Trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Group or the Parent Charitable Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the Trustees' Report and Financial Statements, other than the financial statements and our auditor's report thereon. The other information comprises the Trustees' Report. The Trustees are responsible for the other information.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report, which includes the Directors' Report prepared for the purposes of Company Law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report, which is included in the Trustees' Report, has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatement in the Trustee's report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion;

- adequate accounting records have not been kept by the Parent Charitable Company, or returns adequate for our audit have not been received from branches not visited by us; or
- the Parent Charitable Company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime; or were not entitled to take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the Parent Charitable Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council's ("FRC's") website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the Charitable Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charitable Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company and the Charitable Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Phil Cliftlands (Senior Statutory Auditor)
For and on behalf of BDO LLP, statutory auditor
Gatwick

Date:

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND
EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2019

	Note	Unrestricted funds 2019 £	Total funds 2019 £	Total funds 2018 £
Income and endowments from:				
Donations - research grants		714,660	714,660	1,098,270
Charitable Activities		643,086	643,086	1,121,511
Other trading activities		2,360,980	2,360,980	1,056,182
Interest receivable		1,057	1,057	469
Total income and endowments		3,719,783	3,719,783	3,276,432
Expenditure on:				
Costs of other trading activities	4	1,768,342	1,768,342	903,727
Charitable activities	4	1,687,265	1,687,265	2,315,603
Total expenditure		3,455,607	3,455,607	3,219,330
Net income before other recognised gains and losses		264,176	264,176	57,102
Net movement in funds		264,176	264,176	57,102
Reconciliation of funds:				
Total funds brought forward		78,614	78,614	21,512
Total funds carried forward		342,790	342,790	78,614

The notes on pages 14 to 24 form part of these financial statements.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)
REGISTERED NUMBER: 09848965

CONSOLIDATED BALANCE SHEET
AS AT 31 DECEMBER 2019

	Note	£	2019 £	£	2018 £
Fixed assets					
Tangible assets	9		6,747		-
Current assets					
Debtors	10	1,050,340		608,839	
Cash at bank and in hand	14	<u>327,227</u>		<u>280,473</u>	
		1,377,567		889,312	
Creditors: amounts falling due within one year	11	<u>(1,041,524)</u>		<u>(810,698)</u>	
Net current assets			<u>336,043</u>		<u>78,614</u>
Net assets			<u>342,790</u>		<u>78,614</u>
Charity Funds					
Unrestricted funds			<u>342,790</u>		<u>78,614</u>
Total funds			<u>342,790</u>		<u>78,614</u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Trustee

Trustee

Date:

Date:

The notes on pages 14 to 24 form part of these financial statements.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)
REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2019

	Note	£	2019 £	£	2018 £
Fixed assets					
Tangible assets	9		6,747		-
Investments			<u>1</u>		<u>1</u>
			6,748		1
Current assets					
Debtors	10	969,031		632,572	
Cash at bank	14	<u>145,407</u>		<u>125,968</u>	
		1,114,438		758,540	
Creditors: amounts falling due within one year	11	<u>(778,396)</u>		<u>(679,927)</u>	
Net current assets			<u>336,042</u>		<u>78,613</u>
Net assets			<u>342,790</u>		<u>78,614</u>
Charity Funds					
Unrestricted funds			<u>342,790</u>		<u>78,614</u>
Total funds			<u>342,790</u>		<u>78,614</u>

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.

The profit after tax of the parent Company for the year was £264,176 (2018 - £57,102).

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Trustee

Trustee

Date:

Date:

The notes on pages 14 to 24 form part of these financial statements.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2019

	Note	2019 £	2018 £
Cash flows from operating activities			
Net cash used in operating activities	13	<u>55,614</u>	<u>(3,457)</u>
Cash flows from investing activities:			
Purchase of tangible fixed assets		<u>(8,860)</u>	<u>-</u>
Net cash used in investing activities		<u>(8,860)</u>	<u>-</u>
Change in cash and cash equivalents in the year		46,754	(3,457)
Cash and cash equivalents brought forward		<u>280,473</u>	<u>283,930</u>
Cash and cash equivalents carried forward	14	<u><u>327,227</u></u>	<u><u>280,473</u></u>

The notes on pages 14 to 24 form part of these financial statements.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The Office of Health Economics ("the company") meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Statement of financial activities (SOFA) and Balance sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the company alone as permitted by section 408 of the Companies Act 2006.

The net income and expenditure for the period dealt with in the accounts of the parent company was £264,176 (2018 - £57,102).

In considering whether it continues to be appropriate to prepare financial statements on a going concern basis the Trustees have considered both the ongoing support from the ABPI and the evaluation of Covid-19 by the ABPI's Governance Committee which concludes that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements.

1.2 Company status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Consultancy project income is included to the extent that it has been earned in the period by reference to appropriate project milestones or project completion. Payments received in advance for consultancy projects are included in Creditors (Other Creditors) to the extent that these have not been earned in the period.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

1.6 Tangible fixed assets and depreciation

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of Financial Activities.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures and fittings	-	25% straight line
-----------------------	---	-------------------

1.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.8 Cash and Cash Equivalents

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1.9 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.10 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments.

Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.11 Foreign currencies

The company's and group's functional and presentational currency is GBP.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the Balance sheet date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Consolidated Statement of Financial Activities incorporating the income and expenditure account.

1.12 Pensions

Another group entity operates a defined contribution pension scheme and the pension charge represents the amounts which have been recharged by another group entity in respect of the staff pensions payable to the funds in respect of the year.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

1.13 Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgment:

(a) Impairment of trade and other debtors

The company makes an estimate of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the credit rating of the debtor, ageing profile of the debtors and historical experience. See Note 10 for the net carrying amount of debtors.

(b) Accrued and deferred income

The group estimates the amount of any income generated but not invoiced to customers at the year-end, or vice versa, based on the extent of services provided and what is expected to be invoiced after the period end, or already been invoiced before the period end.

2. Charitable activities

	Unrestricted	Total	<i>Total</i>
	£	2019	<i>2018</i>
		£	£
Direct charitable expenditure	1,532,722	1,532,722	2,059,362
Support costs – governance (Note 3)	30,598	30,598	43,190
Support costs – general (Note 3)	123,945	123,945	213,051
	<u>1,687,265</u>	<u>1,687,265</u>	<u>2,315,603</u>

Included within Direct charitable expenditure are staff costs totalling £882,549 (2018 - £1,225,486). A further £1,207,044 (2018 - £638,101) of staff costs are included within OHE Consulting Limited trading activities within Note 4. An analysis of total staff costs of £2,089,593 (2018 - £1,859,059), is provided in Note 6.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

3. Support costs

	Governance £	General £	Total 2019 £	Total 2018 £
Legal and professional related costs	6,018	-	6,018	9,768
Accountancy related costs	24,580	-	24,580	33,422
Human resources related costs	-	17,821	17,821	25,962
Facilities related costs	-	5,595	5,595	7,933
IT related costs	-	18,096	18,096	55,038
Other office support related costs	-	82,433	82,433	124,118
	<u>30,598</u>	<u>123,945</u>	<u>154,543</u>	<u>256,241</u>
<i>Total 2018</i>	<u>43,190</u>	<u>213,051</u>	<u>256,241</u>	

4. Analysis of Expenditure by expenditure type

	Other costs 2019 £	Other costs 2018 £
OHE Consulting trading activities	1,768,342	903,727
	<u>1,768,342</u>	<u>903,727</u>
Direct charitable expenditure	1,532,722	2,059,362
General support costs	123,945	213,051
	<u>1,656,667</u>	<u>2,272,413</u>
Charitable activities		
Expenditure on governance	30,598	43,190
	<u>1,687,265</u>	<u>2,315,603</u>
Total Expenditure	<u>3,455,607</u>	<u>3,219,330</u>

5. Auditors' remuneration

	2019 £	2018 £
Fees payable to the company's auditor and its associates in respect of:		
Audit-related assurance services	<u>7,000</u>	<u>6,300</u>

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

6. Staff costs

Staff costs, including key management personnel (Note 7), were as follows:

	2019	2018
	£	£
Wages and salaries	1,757,923	1,569,640
Social security costs	207,660	182,575
Cost of defined contribution scheme (Note 15)	<u>124,010</u>	<u>106,844</u>
Total	<u>2,089,593</u>	<u>1,859,059</u>

Included within staff costs and key management personnel costs (Note 7) are settlement payments of nil (2018 - £30,000) to an ex-employee for leaving office.

The average number of employees during the period was as follows:

	2019	2018
	No.	No.
Executive management team	3	4
Administrative staff	<u>20</u>	<u>16</u>
	<u>23</u>	<u>20</u>

The number of higher paid employees was:

	2019	2018
	No.	No.
In the band £60,001 - £70,000	2	1
In the band £70,001 - £80,000	2	1
In the band £80,001 - £90,000	0	1
In the band £90,001 - £100,000	1	0
In the band £130,001 - £140,000	0	1
In the band £140,001 - £150,000	0	1
In the band £160,001 - £170,000	1	1
In the band £170,001 - £180,000	1	0
In the band £260,001 - £270,000	1	0
In the band £290,001 - £300,000	<u>0</u>	<u>1</u>

The above bandings include salary, performance related bonus and any cash allowances.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

7. Key management personnel

	2019 £	2018 £
Wages and salaries	527,391	736,903
Social security costs	67,762	91,364
Cost of defined contribution scheme (Note 15)	<u>31,711</u>	<u>36,401</u>
Total	<u>626,864</u>	<u>864,668</u>

In addition to the Board of Trustees, there were 3 (2018 - 4) key management personnel, 3 (2018 - 3) of which accrued benefits under another group entity's defined contribution pension scheme during the period

8. Trustees' fees

	2019 £	2018 £
Fees for services provided and reimbursed expenses	<u>22,392</u>	<u>22,837</u>

The highest paid Trustee received remuneration of £NIL (2018 - £NIL).

B Jonsson, Trustee, received fees for services provided during the period, including reimbursed expenses, of £4,888 (2018 - £2,350).

M Drummond, Trustee, received fees for services provided during the period, including reimbursed expenses, of £15,084 (2018 - £20,487).

A Charlesworth, Trustee, received fees for services provided during the period, of £2,420 (2018 - £Nil).

The fees and expenses paid to the three Trustees noted above during the period related to the provision of consultancy and advisory services in respect of direct charitable activities. This directly contributed to the company achieving its objectives.

The services provided by the Trustees relates to advice in respect of specialist areas within health economics and healthcare policy and hence it would have proven difficult to obtain these services from a third party.

No Trustees received fees for being Trustees and no other remuneration or expenses were paid to the Trustees during the period.

The above payments were made in line with the authority contained within the Charity's memorandum and articles of association.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

9. Tangible fixed assets

Group and Company	Fixtures and fittings £
Cost	
At 1 January 2019	-
Additions	<u>8,860</u>
At 31 December 2019	<u>8,860</u>
Depreciation	
At 1 January 2019	-
Charge for the year	<u>2,113</u>
At 31 December 2019	<u>2,113</u>
Net book value	
At 31 December 2019	<u><u>6,747</u></u>
At 31 December 2018	<u><u>-</u></u>

10. Debtors

	<u>Group</u>		<u>Company</u>	
	2019 £	2018 £	2019 £	2018 £
Trade debtors	481,852	468,627	41,626	121,422
Amounts owed by group undertakings	91,129	5,327	787,223	376,265
Other debtors	643	1,779	643	1,779
Prepayments and accrued income	476,716	133,106	139,539	133,106
	<u>1,050,340</u>	<u>608,839</u>	<u>969,031</u>	<u>632,572</u>

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

11. Creditors: Amounts falling due within one year

	<u>Group</u>		<u>Company</u>	
	2019 £	2018 £	2019 £	2018 £
Trade creditors	21,772	10,180	20,894	10,180
Amounts owed to parent company	386,114	511,068	386,114	511,068
Accruals and deferred income	633,638	289,450	371,388	158,679
	<u>1,041,524</u>	<u>810,698</u>	<u>778,396</u>	<u>679,927</u>

12. Financial instruments

	2019 £	2018 £
Financial assets measured at fair value through income and expenditure	327,227	280,473
Financial assets measured at amortised cost	<u>589,149</u>	<u>608,839</u>
	<u>916,376</u>	<u>889,312</u>
Financial liabilities measured at cost less impairment	<u>691,577</u>	<u>734,245</u>

Financial assets measured at fair value through income and expenditure comprise of cash and cash equivalents.

Financial assets measured at amortised cost comprise of debtors falling due within one year, excluding accrued income.

Financial liabilities measured at cost less impairment comprise of creditors falling due within one year, excluding deferred income.

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019**

13. Reconciliation of net movement in funds to net cash flow from operating activities

	Group	
	2019	2018
	£	£
Net income for the year (as per Statement of Financial Activities)	264,176	57,102
Adjustment for:		
Depreciation of tangible assets	2,113	
(Increase)/decrease in debtors	(441,501)	22,293
Increase/(decrease) in creditors	230,826	(82,852)
	55,614	(3,457)
Net cash provided by/(used in) operating activities	55,614	(3,457)

14. Cash and cash equivalents

	Group		Company	
	2019	2018	2019	2018
	£	£	£	£
Cash at bank and in hand	327,227	280,473	145,407	125,698
	327,227	280,473	145,407	125,698
	327,227	280,473	145,407	125,698

15. Pension commitments

The ultimate parent entity operates a defined benefit contribution pension scheme. The pensions cost charge represents contributions which were payable, and were recharged by another group entity for staff undertaking work on behalf of the OHE Group, and amounted to £124,010 (2018 - £106,844).

16. Related party transactions

During the period three Trustees received fees for services totalling £22,392 (2018 - £22,837) (refer to Note 8 for details). At the balance sheet date, no amount (2018 - £Nil) of this was outstanding.

During the period the company received research grants totalling £714,660 (2018 - 1,098,270) from the ABPI (refer to Note 18 below).

During the period, the group and company incurred support costs totalling £364,660 and £154,543 respectively (2018 - £390,850 and £256,241), which were recharged by the ABPI (refer to Note 17 below).

During the current and comparative period, the company received a transfer of profits from OHE Consulting Limited, which were transferred via Gift Aid (refer to Note 18 below).

THE OFFICE OF HEALTH ECONOMICS

(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

17. Ultimate parent undertaking and controlling party

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales 09826787, by virtue of it being the sole member of the company. The Association represents innovative research based biopharmaceutical companies, large, medium and small, leading an exciting era of bioscience in the UK. This company prepares consolidated financial statements. These are available to the public and may be obtained from 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT.

18. Principal subsidiaries

OHE Consulting Limited

Company name	Country of incorporation	Percentage Shareholding	Description
OHE Consulting Limited	United Kingdom	100 %	Provision of policy and strategic expertise on healthcare and related matters.

During the period, OHE Consulting Limited, registered company number 09853113, generated income totalling £2,360,980 (2018 - £1,056,182), and incurred expenditure totalling £1,768,342 (2018 - £903,729), generating profits for the period of £593,202 (2018 - £152,643). OHE Consulting Limited elected to transfer its profits, by Gift Aid, to the company leaving aggregated assets in OHE Consulting Limited of £Nil at the period end.

19. Post balance sheet events

There have been no significant events since the year end affecting the company except for the increasing business and societal disruption caused by Government measures taken to combat Covid-19. The ABPI have completed an evaluation of Covid-19's potential impact and concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements.

OHE



Research Summary for 2019 for the Charity Report 2020

RESEARCH COMMITTEE REPORT
S 2020

Mireia Jofre-Bonet
Office of Health Economics, London

Table of Contents

1. Foreword	1
2. Review of OHE's research programme in 2019	1
4.1 Core-funded Projects.....	1
4.2 Research Output.....	5
4.2.1 Publications:.....	5
External Journals	5
OHE peer-reviewed	7
Working papers in external sites	9
4.2.2 Research Grants and Research Projects.....	9
4.3 Lunch-time Seminars.....	10
4.4 Brown-Bag Programme.....	11
4.5 OHE Annual Lecture 2019.....	11
4.6 Other contributions by OHE to Research Output.....	12
4.6.1 External presentations by OHE staff.....	12
4.6.2 Advisory roles held by OHE staff members.....	27
4.6.3 Examples of OHE's impact.....	29
5 Research Plans for 2020	30
5.1 General Research Strategy.....	30
5.2 Research Plans by Theme and Presentation by Leads.....	31
Judging Value for Money and Improving Decision-Making (Martina Garau).....	32
Economics of Innovation (Mikel Berdud).....	33
Incentivising Quality (Margherita Neri).....	34
Measuring and valuing outcomes (Patricia Cubí-Mollá).....	35
6 Update on status of Independent Research Organisation Application	37
7 Concluding Remarks	38

1. Foreword

This report contains the summary of OHE research output in 2019 accompanying the **Charity Report for 2019**.

2. Review of OHE's research programme in 2019

Below, we present a summary of all research output produced by OHE in 2019 organised in core funded projects by theme, publications, and research grants.

4.1 Core-funded Projects

Economics of innovation

Project	Investigators	Update on progress
Establishing a reasonable price for an orphan drug	Mikel Berdud, Adrian Towse; Mike Drummond (York)	OHE Research Paper published in Jul 2018 ; manuscript submitted to <i>Applied Health Economics and Health Policy</i> in 2019.
Open innovation – at which state of R&D collaboration might be more socially beneficial than competition	Adrian Towse; Jorge Mestre-Ferrandiz (OHE Visiting Fellow), Thomas Grieve (Oxford)	Early draft of paper ready but Thomas Grieve has now left Oxford and the project. https://abpi.app.box.com/folder/87607364487
Adaptive Pathways	Adrian Towse, Mikel Berdud; Jorge-Mestre-Ferrandiz (OHE Visiting Fellow), Liz Fenwick (Pharmerit), Adam Heathfield (Pfizer)	1. OHE Research Paper (Berdud et al.: Modelling the value of early access schemes and adaptive pathway approaches) – ready for publication subject to final internal review by Adrian Towse. 2. OHE Research Paper (Towse and Fenwick: Use of Vol to analysis managed entry agreements and adaptive pathways) – in progress
Foresight study on European stakeholder appraisal of diagnostics to manage antimicrobial resistance	Grace Hampson, Adrian Towse, David Mott; Michael Hopkins, Martin Llewelyn, Andy Stirling, Frederique Lang (Sussex); Jorge Mestre-Ferrandiz (OHE Visiting Fellow)	A paper containing the lay survey results has been published in Applied Health Economics and Health Policy , with an accompanying blog . The authors plan to put together a policy brief upon publication of the 2 nd paper.
Economics of innovative payment models compared with single pricing of pharmaceuticals	Amanda Cole, Adrian Towse, Bernarda Zamora; Paula Lorgelly (ex-OHE), Richard Sullivan (KCL)	Manuscript prepared and with the authors for internal review. First preference is for submission to <i>Journal of Cancer Policy</i> – submitted in Q2 2019.

Project	Investigators	Update on progress
Debate on indication-based pricing, and how it has been implemented in practice	Amanda Cole, Adrian Towse, Bernarda Zamora	Dropped, and material combined with paper above on economics of innovative payment mechanisms.
Indication-Based Pricing Green Paper. Should drug prices differ by indication?	Amanda Cole, Adrian Towse, Bernarda Zamora	Briefing. Published May 2019.
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C	Mikel Berdud, Martina Garau, Margherita Neri, Phill O'Neill, Chris Sampson, Adrian Towse	Published as an OHE Research Paper . Journal submission to <i>Applied Health Economics & Health Policy</i> .
Barriers to Uptake of Minimal Access Surgery in the United Kingdom	Phill O'Neill, Chris Sampson, Amanda Cole	One manuscript being prepared for submission to BJU International. Awaiting action from original client. https://abpi.app.box.com/folder/70417601279
Value of Innovative Medicines: The Case of Risperidone and Second-generation Antipsychotics?	Mikel Berdud	On-going.
A Dynamic Approach to Pharmaceutical Regulation: VBP and welfare maximisation	Mireia Jofre-Bonet; Niccolo Stamboglis (City); Alistair McGuire (LSE); and Sabine Grimm (Maastricht University Medical Centre)	This paper that has been now rewritten in collaboration with PhD student Niccolo. We are preparing to submit it to a peer review journal by December 2019. A blog post will be written when we have the final version. https://abpi.app.box.com/folder/89673561458
Patients' choice and hospital quality competition: Unintended impacts of the signals	Tommaso Gabrieli (UCL); Mireia Jofre-Bonet, Alistair J. McGuire (LSE); and Matthew Skellern (NHS Improvement)	Work in progress.

Judging value for money and improving decision-making

Project	Investigators	Update on progress
Valuing health at the end of life	Koonal Shah; Aki Tsuchiya (Sheffield), Allan Wailoo (Sheffield)	Fifth paper on project – reporting a study of framing effects and design considerations – published as a <i>NICE DSU Report</i> in Q2 2019. Four other papers already published as journal articles and/or OHE Research Papers. Koonal presented further ideas at a University of Manchester seminar in Q1 2019 and in an organised session at iHEA in July 2019.
Updated Critique of “Methods for the Estimation of the National Institute for Health and Care Excellence Cost Effectiveness Threshold”	Adrian Towse; Sarah Karlsberg (NHS Improvement), Jon Sussex (RAND Europe), Paul Barnsley (Policy Cures Research)	Dropped due to new work published by York. Proposing instead a ‘state of play’ paper by Adrian Towse and Bernarda Zamora
Affordability/ Paying for Cures	Adrian Towse, Grace Marsden; various external co-authors for different parts, notably from CMPT and from ICER	Four papers published (see April 2018 papers). Further paper on uncertainty in ‘cures’ (authored by Adrian Towse and Liz Fenwick, Pharmedit) published in <i>Value in Health</i> .

Project	Investigators	Update on progress
Comparison of the availability and access to orphan medicines in 5 European countries	Bernarda Zamora, Phill O'Neill, Martina Garau	Revised manuscript accepted for publication by <i>Orphanet Journal of Rare Diseases</i> . Editorial published previously in the Government Gazette in 2018.
Critique of CEMIPP Paper	Adrian Towse; Alastair Fischer (OHE Visiting Fellow)	Commentary on the CEMIPP Vaccines Report issued for consultation by the Department of Health (AT and AF were non-voting members of the Committee).
Long-term evaluation of broad mental health interviews	Chris Sampson; Alastair Canaway, (University of Warwick)	Delays due to change in situation for lead author. Continuation uncertain. Abandoned by lead (Canaway).
HTA and payment mechanisms for new drugs to tackle AMR	Olga Rozanova, Grace Hampson and Adrian Towse	In process for OHE publication.
Transparency in Modelling: what, why, who, and how?	Chris Sampson	Article published in <i>PharmacoEconomics</i> : http://dx.doi.org/10.1007/s40273-019-00819-z
Use of Pharmacoeconomics in Drug Reimbursement: What Can We Learn from International Experience?	Chris Sampson, Margherita Neri, Kyann Zhang	Chapter still being drafted.
Public Sector Opportunity Cost	Patricia Cubí-Mollá; Nancy Devlin, Martin Buxton	Developing links with key experts from IFS, HM Treasury, DHSE and others, by socialisation of the topic. Paper submitted to <i>Health Policy</i> (under review).
Blood donation in the UK. Are we doing all right? Could we do better? A comparative study with the Spanish Blood Donation context	Maria Errea, Grace Hampson, Marina Rodes Sanchez	Planned deliverable 1: literature review and discussion paper, to be published as an OHE Research Paper, and potentially submitted to a peer review journal Planned deliverable 2: list of databases or sources which will be explored and analysed Long-term aim is to develop an funded research proposal, for example to Public Health England and/or the NHS B&T Centre

Incentivising quality

Project	Investigators	Update on progress
Variability in the probability of delayed discharge	Bernarda Zamora; Russell Devolder (former OHE placement student)	Forthcoming in <i>Health Policy</i> .
Maternity workforce papers	Graham Cookson, Bernarda Zamora, Margherita Neri; Ioannis Laliotis (LSA)	Currently working on 2 x OHE Research Papers. Presentations at iHEA (July) and due to be presented at HESG (January). Production function paper also presented at LSHTM seminar (October), and c-section one presented at City in December.
Regional inequalities in adiposity in England: a distributional analysis of the contribution of socio-economic position, lifestyles	Apostolos Davillas (OHE); Andrew M. Jones (York)	Paper completed and is under Review at <i>Social Science & Medicine</i> .

Project	Investigators	Update on progress
and the small area obesogenic environment		
Inequality of Opportunity in Health	Apostolos Davillas (OHE); Andrew M. Jones (York)	Published in <i>Journal of Health Economics</i> . The paper also presented at the Royal Statistical Society Conference 2019, 2 – 5 September 2019, Belfast, Northern Ireland. A second working paper published recently (October 2019; https://www.iser.essex.ac.uk/research/publications/working-papers/iser/2019-09.pdf) and published in <i>Health Economics</i> .
Baseline health and public healthcare costs five years on: A predictive analysis using biomarker data in a prospective household panel	Apostolos Davillas (OHE); Steve Pudney (Sheffield)	One paper published at <i>Economics and Human Biology</i> (September 2019; https://doi.org/10.1016/j.ehb.2019.100814). We have published an OHE blog post to highlight the findings and policy relevance of the published paper.

Measuring and valuing outcomes

Project	Investigators	Update on progress
Adaptation to Health States: Sick yet better off?	Patricia Cubí-Mollá, Mireia Jofre-Bonet; Victoria Serra-Sastre, (City)	Paper based on BCS70 published in Health Economics . Paper based on ELSA: presented at conferences; finishing the writing-up.
Can we really compare and aggregate PRO data between people and settings? Implications for clinical trials and HTA	Mike Herdman; Nancy Devlin, Paula Lorgelly (both ex-OHE); Andrea Manca (York)	Published as an OHE Research Paper in Q1 2019; being prepared for journal submission
ISDR – University of Nottingham	Chris Sampson	One paper submitted (<i>Value in Health</i>), rejected, and resubmitted (<i>Quality of Life Research</i>). One paper ready for submission (<i>Diabetes Care</i>). Two papers still being prepared (<i>Diabetes Care, European Journal of Health Economics</i>).
An online DCE study to support the development of an EQ-5D-Y value set for the UK	David Mott; Koonal Shah, Nancy Devlin (both ex-OHE); Oliver Rivero-Arias (Oxford), Juan M. Ramos-Goñi (Axentiva)	Two papers submitted to journals one on incorporating preference heterogeneity (target: <i>Journal of Health Economics</i>) and another comparing adult and adolescent preferences (target: <i>Medical Decision Making</i>). The latter has been published as an OHE Research Paper (July 2019).
Valuing health using EQ-5D: The impact of chronic diseases on the stock of health.	María Errea; Eduardo Sanchez-Iriso, Juan Manuel Cabases (Economics Department, Universidad Pública de Navarra)	Paper published in Health Economics in September 2019
The Blow of Domestic Violence on Children's Health Outcomes	Melcior Rossello-Roig (University of Perugia), Mireia Jofre-Bonet and Victoria Serra-Sastre (City)	This paper was written with former PhD student Melcior Rossello-Roig. We are preparing to submit it to a peer reviewed journal.
Falling off the cliff: The impact of Domestic Violence on Children's Educational Attainment	Melcior Rossello-Roig (University of Perugia), Mireia Jofre-Bonet and	This paper was written with former PhD student Melcior Rossello-Roig. We are preparing to submit it to a peer reviewed journal.

Project	Investigators	Update on progress
	Victoria Serra-Sastre (City)	
Children's Well-being and Maternal Labour Supply	Melcior Rossello-Roig (University of Perugia), Mireia Jofre-Bonet and Victoria Serra-Sastre (City)	This paper was written with former PhD student Melcior Rossello-Roig. We are preparing to submit it to a peer reviewed journal.
Valuing the EQ-5D-Y using a discrete choice experiment: do adult and adolescent preferences differ?	Koonal Shah, Oliver Rivero-Arias, David Mott, Nancy Devlin, Juan Manuel Ramos-Goni	Being submitted to peer reviewed journal.
Uncertainty in patient trade-offs: issues in the reporting of marginal rates of substitution in discrete choice experiments	David Mott; Nour Chami (City), Tommi Tervonen (Evidera)	This is a paper arising from a MSc dissertation completed in September 2019 (Nour Chami). The paper has been <u>published in <i>Value in Health</i></u> (August 2020)

4.2 Research Output:

Our research output falls in several categories: publications; research grants and projects; lunch-time seminars; brown-bag programme.

4.2.1 Publications:

We present our publications in three main groups: publications in external journals; publications on OHE's website (peer reviewed by the OHE reviewing process); and working papers in external institutions.

External Journals

1. Broadbent, D., **Sampson, C.J.**, Wang, A., Howard, L., Williams, A., Howlin, S., Appelbe, D., **Mott, T.**, Cheyne, C., Rahni, M., Kelly, J., Collins, J., García-Fiñana, M., Stratton, I., James, M., and Harding, S. 2019 Individualised Screening for Diabetic Retinopathy: the ISDR study. Rationale, design and methodology for a randomised controlled trial comparing annual and personalised variable-interval risk-based screening. *BMJ Open*. 9(e025788). DOI: [10.1136/bmjopen-2018-025788](https://doi.org/10.1136/bmjopen-2018-025788).
2. **Cubi-Molla, P., Shah, K.**, Garside, J., Herdman, M. and Devlin, N., 2019. A note on the relationship between age and health-related quality of life assessment. *Quality of Life Research*, 28(5), pp.1201-1205. DOI: 10.1007/s11136-018-2071-5.
3. Drummond, M. and **Towse, A.**, 2019. Is rate of return pricing a useful approach when value-based pricing is not appropriate? *A. Eur J Health Econ* (2019) 20: 945. <https://doi.org/10.1007/s10198-019-01032-7>
4. Baltussen, R., Marsh, M., Thokala, P., Diaby, V., Castro, H., Cleemput, I., **Garau, M.**, Iskrov, G., Olyaeemanesh, A., Mirelman, A., Mobinizadeh, M., Morton, A., Tringali, M., van Til, J., Valentim, J., Wagner, M., Youngkong, S., Zah, V., Toll, A., Jansen, M., Bijlmakers, L., Oortwijn, W., Broekhuizen, H.,

2019. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. *Value in Health*, Vol 22 (11), pp 1283-1288,
5. Li, A., Manohar, P.M., Garcia, D.A., Lyman, G.H. and **Steuten, L.M.** 2019. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. *Thrombosis Research*, (180), pp. 37-24. DOI: <https://doi.org/10.1016/j.thromres.2019.05.012>.
 6. Lopez-Picado, A., Barrachina, B., Remon, M. and **Errea, M.**, 2019. Cost-benefit analysis of the use of tranexamic acid in total replacement hip surgery. *Journal of Clinical Anesthesia*. Vol. 57 (in progress. November 2019), pp. 124-128.
 7. Mewes, J.C., Pulia, M.S., Mansour, M.K., Broyles, M.R., Nguyen, B. and **Steuten, L.**, 2019. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. *PLOS ONE*. DOI: <https://doi.org/10.1371/journal.pone.0214222>.
 8. Murad, Z., Stavropoulou, C., and **Cookson, G.** 2019. Incentives and gender in a multi-task setting: An experimental study with real-effort tasks, *PLOS ONE*, 14(3), e0213080. DOI: <https://doi.org/10.1371/journal.pone.0213080>.
 9. Sanchez-Iriso, E., **Errea, M.**, Cabases, J.M., 2019. Valuing Health using EQ-5D: The impact of chronic diseases on the stock of health. *Health Economics*. [Accepted on August 2nd. Publication pending].
 10. **Sampson, C.J.**, Arnold R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how? *PharmacoEconomics*. DOI: [10.1007/s40273-019-00819-z](https://doi.org/10.1007/s40273-019-00819-z).
 11. **Steuten, L.**, Garmo, V., Phatak, H., Sullivan, S.D., Ngheim, P. and Ramsey, S.D. 2019. Treatment patterns, overall survival, and total healthcare costs of advanced Merkle cell carcinoma in the USA. *Applied Health Economics and Health Policy*, pp. 1-8. DOI: <https://doi.org/10.1007/s40258-019-00492-5>.
 12. **Steuten, L.**, Goulart, B., Meropol, N.J., Pritchard, D. and Ramsey, S.D. 2019. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, (3), pp. 1-10. DOI: 10.1200/CCI.19.00002.
 13. **Zamora, B.**, Gurupira, M., **Rodés Sánchez, M.**, Feng, Y., Hernandez-Villafuerte, K., Brown, J. and Shah, K., 2019. The value of international volunteers experience to the NHS. *Globalization and Health*, 15(31). DOI: <https://doi.org/10.1186/s12992-019-0473-y>.
 14. **Zamora, B.**, Maignen, F., **O'Neill, P.**, Mestre-Ferrandiz, J. and **Garau, M.**, 2019. Comparing access to orphan medicinal products in Europe. *Orphanet Journal of Rare Diseases*, 14(1), pp.95.
 15. **Davillas, A.** and Pudney, S. (2019) Biomarkers as precursors of disability. *Economics of Human Biology* Available online 10 September 2019, 100814. <https://www.sciencedirect.com/science/article/pii/S1570677X18300959?via%3Dihub>
 16. **Davillas, A.**, & Jones, A. M. (2019). Ex ante inequality of opportunity in health, decomposition and distributional analysis of biomarkers. *Journal of Health Economics*, 102251. <https://doi.org/10.1016/j.jhealeco.2019.102251>
 17. Wurcel, V., Cicchetti, A., Garrison, L., Kip, M.M., Koffijberg, H., Kolbe, A., Leeflang, M.M., Merlin, T., Mestre-Ferrandiz, J., Oortwijn, W. and Oosterwijk, C., Tunis, S., **Zamora, B.** 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. *Public Health Genomics*, pp.1-8.

18. **Mott, D.J., Hampson, G.,** Llewelyn, M., Mestre-Ferrandiz, J. and Hopkins, M.M. A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. *Applied Health Economics and Health Policy*. doi: 10.1007/s40258-019-00516-0
19. Hilari, K., Behn, N., Marshall, J., Simpson, A., Thomas, S., Northcott, S., Flood, C., McVicker, S., **Jofre-Bonet, M.**, Moss, B., James, K. and Goldsmith, K., 2019. Adjustment with aphasia after stroke: study protocol for a pilot feasibility randomised controlled trial for Supporting wellbeing through PEeR Befriending (SUPERB). *Pilot and Feasibility Studies*, 5(1), p.14.
20. Kuper, H., Lyra, T.M., Moreira, M.E.L., de Albuquerque, M. do S.V., de Araújo, T.V.B., Fernandes, S., **Jofre-Bonet, M.**, Larson, H., Lopes de Melo, A.P., Mendes, C.H.F., Moreira, M.C.N., do Nascimento, M.A.F., Penn-Kekana, L., Pimentel, C., Pinto, M., Simas, C. and Valongueiro, S., 2019. Social and economic impacts of congenital Zika syndrome in Brazil: Study protocol and rationale for a mixed-methods study. *Wellcome Open Research*, 3, p.127
21. Garrison L and **Towse A.** (2019) A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine. *J Manag Care Spec Pharm*. 2019;25(10):1082-87
22. Pearson SD, Segel C, **Cole A**, Henshall C, and **Towse A.** 2019. Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit. *J. Comp. Eff. Res.* 10.2217/cer-2019-0094 C
23. **Towse A.**, and Fenwick E. (2019) Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment? *Value in Health*. 2019; 22(6):677–683.

OHE peer-reviewed

Hampson, G., Mott, D., Shah, K., and Devlin, N., 2018. Public Preferences for Health Gains and Cures: A Discrete Choice Experiment. OHE Consulting Report, London: Office of Health Economics <https://www.ohe.org/news/public-preferences-health-gains-and-cures-discrete-choice-experiment>

Cole, Amanda, Patricia Cubi-Molla, Jack Pollard, Duncan Sim, Richard Sullivan, Jon Sussex, and Paula Lorgelly. Making Outcome-Based Payment a Reality in the NHS. OHE working paper, No. 002115. 2019. <https://www.ohe.org/publications/making-outcome-based-payment-reality-nhs>

Hernandez-Villafuerte, K., **Zamora, B.**, Feng, Y., Parkin, D., **Devlin, N., Towse, A.,** 2019. Exploring Variations in the Opportunity Cost Cost-Effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England. Research Paper 19/03, Office of Health Economics. <https://www.ohe.org/news/exploring-variations-opportunity-cost-cost-effectiveness-threshold-clinical-area-results>

Sampson, C. and Garau, M. 2019. How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy. OHE briefing, London: Office of Health Economics <https://www.ohe.org/publications/how-should-we-measure-quality-life-impact-rare-disease-recent-learnings-spinal-muscular>

Berdud, M., Chalkidou, K., Dean, E., Ferraro, J., Garrison, L., Nemzoff, C. and **Towse, A.**, 2019. The Future of Global Health Procurement: Issues around Pricing Transparency. Research paper 19/04. Office of Health Economics. <https://www.ohe.org/publications/future-global-health-procurement-issues-around-pricing-transparency#>

Brassel, S., Rozanova, O., and Towse, A., 2019. The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for HTA and Value Assessment. OHE Research Paper, London: Office of Health Economics.
<https://www.ohe.org/news/who-technical-report-pricing-cancer-medicines-missing-central-role-value-assessment>

Devlin, N., Lorgelly, P. and Herdman, M., 2019. Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA. OHE Research Paper.
<https://www.ohe.org/news/can-we-really-compare-and-aggregate-patient-reported-outcomes-between-people-and-settings>

Cole, A., Towse, A & Zamora, B. 2019. Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? OHE briefing, London, Office of Health Economics
<https://www.ohe.org/publications/indication-based-pricing-ibp-discussion-paper-should-drug-prices-differ-indication#>

Cole, A., Towse, A & Zamora, B. 2019. Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
<https://www.ohe.org/publications/documento-de-debate-sobre-la-fijación-de-precios-en-función-de-la-indicación-ibp-¿deben>

Berdud, M., Wallin-Bernhardsson, N., Zamora, B., Lindgren, P., and Towse, A. (2019). Value of Innovative Medicines: The Case of Risperidone and Second-generation Antipsychotics? OHE Research Paper, London. Office of Health Economics
<https://www.ohe.org/publications/case-risperidone-assessing-life-cycle-value-second-generation-antipsychotics-sweden-and#>

Zamora, B., Cookson, G., Garau, M., 2019. Unrelieved Pain in Palliative Care in England. OHE Consulting Report. London: Office of Health Economics. Available at:
<https://www.ohe.org/publications/unrelieved-pain-palliative-care-england>

Yasunaga, H., Yamana, H., **Rodes Sanchez, M. and Towse, A.,** 2019. Data Governance Arrangements for Real-World Evidence in Japan. OHE Consulting Report, London: Office of Health Economics.
<https://www.ohe.org/news/data-governance-arrangements-real-world-evidence-japan>

Neri, M., Hampson, G., Henshall, C. and Towse, A., 2019. HTA and payment mechanisms for new drugs to tackle AMR. OHE Research Paper, London: Office of Health Economics. Available at:
<https://www.ohe.org/publications/hta-and-payment-mechanisms-new-drugs-tackle-amr>

OHE not peer-reviewed

Cole, A., Towse, A., Segel C.S., Henshall, C., Pearson, S.D. Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates. Institute for Clinical and Economic Review and the Office of Health Economics.

OHE Annual Report to the Charity commission for the year 2018, London: Office of Health Economics. Available at <https://www.ohe.org/publications>

Working papers in external sites

Yaman, F., **Cubi-Molla, P.** and Ungureanu, S., 2019. Which Decision Theory Describes Life Satisfaction Best? Evidence from Annual Panel Data. Discussion Paper Series (19/12). Department of Economics, City, University of London.

https://openaccess.city.ac.uk/id/eprint/22492/1/Dept_Econ_WP1912.pdf

4.2.2 Research Grants and Research Projects

Since November of 2018, OHE has won two **research grants**, one from IFPMA and another from the Health Foundation:

- Critique of the WHO report 'Pricing of cancer medicines and its impacts'
Funder: **IFPMA**
OHE investigators: Simon Brassel, Olga Rozanova, Adrian Towse
Theme(s): Judging value for money and improving decision-making
Grant: £30,318
OHE Income: £29,818
- Improving Labour Productivity in Primary Care: the role of skill mix, technology, and patients
Funder: **Health Foundation**
OHE investigators: Graham Cookson, Patricia Cubi-Molla, Bernarda Zamora, Margherita Neri
External investigators: Simon de Lusignan (University of Oxford)
Theme(s): Incentivising quality
Grant: £499,972
OHE Income: £286,133

OHE's has bid for six other mostly large funding calls including the MRC and the NIHR in 2019 but we have been unsuccessful except for the grant to e-nurture for which we have been asked to resubmit the application with their input.

Funded Research projects won in 2019:

Project	Project Won	Budget Total
5060 - Thresholds in public health programs: inter and intra-country threshold benchmarking. Amgen AU	06-Oct-19	£89,227
5086 - Critique of WHO Report IFPMA	01-Jan-19	£29,810
EE60 - EQ-5D Bolt-on Development EuroQol Research Foundation	01-Jan-19	£38,011
EE64 - Implementing Augmented Cost-Effectiveness Analysis: Challenges and Next Steps University of Washington	01-May-19	£35,846
EE65 - CQUINN interventions	01-Jan-19	£37,644
EE67 - MIC Part 2 Centre for Global Development	01-Jan-19	£35,099
P2 - Making Outcome-Based Payment a Reality in the NHS - Phase 2 Cancer Research UK (CRUK)	20-Aug-19	£89,307
P21 - Infertility Utilities Ferring Pharmaceuticals Ltd	05-Aug-19	£225,595
Total Funded Research Projects		£580,539

Overall, independently raised funding for research in 2019 was £896,490 (research grants plus funded research projects) in 2019.

4.3 Lunch-time Seminars

OHE has a main programme seminar series, the lunchtime seminars, and a more informal brown-bag lunch seminar. This section provides an update on both.

OHE LUNCHTIME SEMINARS

Between April and end of October of 2019, there have been five OHE Lunchtime Seminars (on top of the two held between January and March, for a total of 7 from January to October 2019). The subjects range from health care system reforms, to how to measure the true value of treatments, by adjusting the measurement of improvements to specific conditions.

I. OHE LUNCHTIME SEMINAR: CLOSING THE 'KNOW-DO' GAP FOR HEALTH SYSTEMS REFORM AT THE POLICY LEVEL

Event date: Monday, 14 October 2019

OHE Lunchtime Seminar with Rafael Bengoa, Institute for Health and Strategy and David Hunter, Newcastle University entitled "Closing the 'Know-Do' Gap for Health Systems Reform at the Policy Level".

II. OHE LUNCHTIME SEMINAR: HOW DO WE MEASURE THE 'VALUE' IN VALUE - BASED CARE?

Event date: Tuesday, 17 September 2019

Steve McKenna, Galen Research and University of Manchester. The seminar presented a model for value-based healthcare developed by Galen Research which measures outcomes in terms of patients' fundamental needs. Under the leadership of Professor Stephen McKenna, Galen Research have developed over 30 disease-specific measures of patients' needs, each of which has been adapted for use in over 60 countries.

III. OHE LUNCHTIME SEMINAR: HEALTH YEARS IN TOTAL (HYT): A NEW HEALTH OBJECTIVE FUNCTION FOR COST-EFFECTIVENESS ANALYSIS

Event date: Wednesday, 24 July 2019

In this seminar, Ariban Basu examined conceptual and theoretic arguments for use of HYT and illustrate their performance against QALYs and EVL. Methods to calculate HYT in a CEA model, to derive CEA thresholds for HYT corresponding to the QALY-based thresholds in the US and policy implications for the use of HYT using recently published technology evaluations was also presented.

IV. OHE LUNCHTIME SEMINAR: INCENTIVES FOR R&D, COMPETITION, AND INTERTEMPORAL EFFECTS OF PAYMENT RULES FOR CURES

Event date: Thursday, 6 June 2019

Prof. Pedro Pita Barros examined how enlarging the set of possible pricing rules to those that include an intertemporal perspective can incentivise efficient investment in pharmaceutical R&D.

V. OHE LUNCHTIME SEMINAR: CASCADES OF CARE IN HEALTH POLICY ANALYSIS AND PLANNING

Event date: Monday, 29 April 2019

'Cascades of care' have emerged as an attractive tool for assessing access to care for numerous chronic diseases, including HIV/AIDS, addiction, diabetes, hepatitis, mental health, and tuberculosis. In this seminar Dr. Haacker discussed the use of cascades of care in health policy analysis and planning and reviewed various examples of its applications. Speaker: Markus Haacker.

4.4 Brown-Bag Programme

- Thu 25/04/2019: Grace Hampson shared her experience during her secondment at Public Health England.
- Mon 03/06/2019: Marina Rodes-Sanchez presented an update on the project PSS CQUIN schemes.
- Mon 01/07/2019: Bernarda Zamora gave a talk on her work on Reconciling ACEA and MCDA
- Tue 09/07/2019: Olga Rozanova shared her progress on the article: Can price-cap regulation increase prices?
- Thu 11/07/2019: Lauren Stewart (Goldsmith University) presented her work on Mental health in the Gambia. This presentation aimed at finding synergies with staff members at OHE for a joint grant.
- Tue 30/07/2019: Fred McElwee (intern from the University of Edinburgh) described his work on A Simulation Model for Performance-Based Risk-Sharing Agreements, done under the supervision of Lotte Steuten.
- Wed 21/08/2019: Wenrong Ye presented 'Cost-Utility analysis of the distant-delivered mindfulness-based intervention for people with Parkinson's Disease', which she had written during her internship at OHE from LSE Health Policy.
- Monday 07/11/2019: Amira El-Shal presented 'Are user fees necessarily evil? Perceived quality of family planning, maternal and child health services in Egypt'.
- Wednesday 27/11/2019: Maria Errea and Dave Mott presented - Composite time trade-off
- Thursday 12/12/2019: Simon Brassel presented – Internal publication management at OHE: Process, Templates, Tips, Tricks and Knowledge exchange

4.5 OHE Annual Lecture 2019

The OHE Annual Lecture 2019 on 15th October was on *The Evolution of U.S. Policy Responses to the Opioid Epidemic* presented by Professor Richard Frank from Harvard University.

Richard G. Frank, PhD, focused on two dimensions of the U.S. response- treatment and harm reduction- placed into the larger context of the American opioid epidemic. He reviewed tools available to federal and state governments for promoting treatment and harm reduction. In particular, he directed attention to economic and regulatory policy and reviewed how they have been deployed. This includes efforts grounded in the health sector, the law enforcement system, and human services. At the end, he provided some suggestions for additional high-impact policy measures that federal and state governments could adopt.

Richard G. Frank, PhD, is the Margaret T. Morris Professor of Health Economics. His research is focused on the economics of mental health and substance abuse care, long term care financing policy, health care competition and implementation of health reform and disability policy. He served

as the deputy assistant secretary for planning and evaluation at the Department of Health and Human Services (DHHS), directing the office of Disability, Aging and Long-Term Care Policy from 2009-2011. From 2014-2016, he served as the DHHS assistant secretary for planning and evaluation. Dr. Frank served as an editor for the Journal of Health Economics for nine years. He was awarded the Carl A. Taube Award from the American Public Health Association and the John Eisenberg Mentorship Award from the National Research Service Awards. He is a member of the National Academy of Medicine. He received the Academy Health Distinguished Investigator Award in June 2018.

He is co-author with Sherry Glied of the book *Better but Not Well* (Johns Hopkins Press). Dr. Frank received his BA in economics from Bard University and his PhD in economics from Boston University.

This 2019 OHE Annual Lecture was attended by about 200 people.

4.6 Other contributions by OHE to Research Output

Below, we list other contributions of OHE staff to research output in the form of presentations to conferences; membership to advisory boards and committees; and, impact on other researchers and policy makers.

4.6.1 External presentations by OHE staff

What follow is a list of all the presentations of OHE members of staff in conferences and other research and policy fora.

NO	PRESENTATION
1	<p>7-9th January 2019 Chris Sampson Event: HESG Presentation: Drop dead: is anchoring at 'dead' a theoretical requirement in health state valuation? Location: University of York, York, UK</p> <p>Numerous methodological difficulties arise from the use of 'dead' as an anchor in health state valuation, in particular the need to value states identified as 'worse than dead'. The aim of this study is to explore the conceptual basis for using 'death' in health state valuation and to consider alternative approaches. This study has received funding from the EuroQol Research Foundation.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
2	<p>7-9th January 2019 Chris Sampson Event: HESG Presentation: Discussion of paper "We now have estimates of the marginal productivity of the NHS: so what?" Location: University of York, York, UK</p> <p>Chris discussed this paper by Mark Sculpher and colleagues from the University of York.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
3	<p>7-9th January 2019 Bernarda Zamora and Adrian Towse Event: HESG Presentation: Exploring Variations in the Opportunity Cost by Clinical Area: Results from a Feasibility Study in England Location: University of York, York, UK</p> <p>This paper provides further empirical evidence on the relationship between health outcomes and health expenditures in England by (1) extending the analysis to include different health outcomes, and (2) examining the relationship between mortality and health expenditures along the mortality distribution. It was discussed by David Glynn of the University of York.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
4	<p>7-9th January 2019 Bernarda Zamora Event: HESG Presentation: Discussion of paper "Estimating the marginal productivity of public health care expenditure in Indonesia: a dynamic panel data approach" Location: University of York, York, UK</p> <p>This paper contributes to the literature by estimating the marginal productivity of public health spending in Indonesia. The main outcome is under-five and infant mortality rate, two health indicators that have exhibited significant improvements over this period.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
5	<p>7-9th January 2019 Koonal Shah Event: HESG Presentation: Discussion of paper "Is aversion to inequalities in health reference-dependent? A pilot study" Location: University of York, York, UK</p> <p>Koonal discussed this paper by Simon McNamara and colleagues from the University of Sheffield.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>

6	<p>29th January 2019 Koonal Shah Event: NICE Technical Briefing Presentation: Generating preference-based values for the EQ-5D-Y to support its use in HTA Location: National Institute for Health and Care Excellence, London, UK</p> <p>This was a joint presentation by Koonal Shah and Oliver Rivero-Arias (University of Oxford). The presentation focused on the normative and practice issues associated with valuing health in children, and then presented findings from some recent empirical research. The audience comprised analysts working for NICE.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
7	<p>29th January 2019 Adrian Towse Event: Duke-Margolis Meeting Presentation: Exploring payment reform pathways for antibiotics from provider and payer perspectives Location: Washington DC, USA</p> <p>As a member of the Duke-Margolis Advisory Committee on Antibiotic Incentives and Payment Reform, Adrian participated in their roundtable table meeting held at the Duke-Margolis Head Office in Washing DC on January 29th.</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
8	<p>1st February 2019 Amanda Cole Event: Computers, Privacy and Data Protection Conference (CPDP) 2019 Presentation: Legal barriers to the better use of health data to deliver pharmaceutical innovation Location: Brussels, Belgium</p> <p>The generation of new sources and uses of health data present significant opportunities for the pharmaceutical industry, but these are bounded by the legal context which dictates what data can be collected and how they can be used. In this presentation, I describe the nature of these legal barriers, particularly within the context of the GDPR, and propose possible solutions.</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION; MEASURING AND VALUING OUTCOMES</p>
9	<p>4th February 2019 Koonal Shah Event: Manchester Centre for Health Economics Seminar Series Presentation: End of life treatments, societal values, and selecting a measure of 'overall' preference Location: University of Manchester, Manchester, UK</p> <p>Koonal gave a seminar to academic researchers based at the University of Manchester. His presentation included an overview of the evidence on public preferences regarding an end of life premium, and a discussion of how to select a measure of 'overall' or average preference.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
10	<p>7th February 2019 Graham Cookson Event: LSHTM Health Economics Seminars Presentation: Cheap & Dirty: The effect of contracting out cleaning on cost and quality Location: London School of Hygiene & Tropical Medicine, London, UK</p> <p>Graham gave a presentation at the LSHTM Health Economics Seminars series on the effect of contracting out cleaning on cost and quality.</p> <p>RESEARCH THEME(S): INCENTIVISING QUALITY</p>
11	<p>25th February 2019 Graham Cookson Event: UCB Patient Access, Pricing and Health Economics team visit Presentation: IBP & VBP: Playing to win</p>

	<p>Location: Brussels, Belgium</p> <p>Graham Cookson and Adrian Towse were invited to speak to the UCB Patient Access team in Brussels. Graham's presentation focused on concentrating UCB's efforts on getting them to understand what their pricing strategy could be for certain drugs and to encourage them to look at steps to implement IBP and what the barriers were to success.</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
12	<p>7th March 2019 Graham Cookson Event: Royal Brompton Weekly Seminar Series Presentation: Orphan Drugs – High Prices: is there a way forward Location: The Royal Brompton Hospital, London, UK</p> <p>Graham started his presentation with an introduction to orphan drugs (as relevant to respiratory medicine) and how they are appraised differently. He went on to discuss some of the problems that relate to high prices of Pharmaceuticals for orphan drugs and how they have frequently poor cost-effectiveness. And then went onto discuss how he felt that there is solution that involves a combination of real-world evidence and outcomes-based contracting</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
13	<p>11-13th March 2019 Koonal Shah Event: EuroQol Association Meeting Presentation: EQ-5D-Y valuation Location: Noordwijk, Netherlands</p> <p>Koonal gave a brief presentation to EuroQol members about work that OHE had been leading on the valuation of health in children and adolescents. The presentation covered an analysis of normative issues and an overview of three empirical studies.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
14	<p>13th March 2019 Chris Sampson Event: SMaRteN Sandpit – What is Distinctive About Student Mental Health? Presentation: An economic perspective Location: King's College, London, UK</p> <p>Chris provided an overview of the relevance of economics in the context of student mental health, discussing preferences and opportunity costs. The talk was aimed at a general research audience.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
15	<p>19-21st March 2019 Lotte Steuten Event: World Pharma Pricing and Market Access Presentation: Pay for performance: discussing the first large scale study into efficacy of the model Location: Amsterdam, Netherlands</p> <p>Discussion on how to move value-based oncology-drug pricing discussions from 'talk to data'. Described how we design and test, with guidance from national key opinion leaders, a value-based oncology drug pricing model suitable for evaluation in a pragmatic trial. Target audience was members of the pharma industry, payers and policy makers.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
16	<p>20th March 2019 Bernarda Zamora Event: n/a Presentation: Health Financing: Towards Universal Coverage Location: De Vere Grand Connaught Rooms, London, UK</p>

	<p>Bernarda was invited to be a guest on Health Financing to achieve Universal Health Coverage for the Professional Certificate in Strategic Health Planning run by the International Centre for Parliamentary Studies. Her lecture focused on Health Financing to achieve Universal Health Coverage.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
17	<p>27th March 2019 Adrian Towse Event: HERC Seminar Presentation: Exploring variations in the opportunity cost by clinical area: results from a feasibility study in England Location: Nuffield Department of Primary Care, Oxford, UK</p> <p>Adrian presented results from his study on the outcomes and health expenditures in England.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
18	<p>28th March 2019 Grace Hampson Event: The real cost of the UK's poor fruit consumption Presentation: The Real Cost of the UK's Poor Fruit Consumption Location: London, UK</p> <p>The purpose of this talk was to discuss the dangers and wider health/economic implications of low fruit and veg consumptions (including NHS, economy and global disease burden).</p> <p>RESEARCH THEME(S): NONE APPLY</p>
19	<p>4th April 2019 Koonal Shah Event: Webinar for the GSK Patient-Reported Outcomes Group Presentation: Directly eliciting personal utility functions Location: Online (webinar)</p> <p>Koonal presented the methods and findings of an OHE-led study that developed a new approach to valuing health-related quality of life. The audience comprised health outcomes analysts working for GSK in the United States.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
20	<p>5th April 2019 Koonal Shah Event: iHEA Health Preference Special Interest Group Webinar Presentation: Adult versus adolescent preferences for EQ-5D-Y health states Location: Online (webinar)</p> <p>Koonal discussed the normative and practical challenges involved in valuing health in children, before presenting the methods and findings of two recent EQ-5D-Y valuation studies. The audience comprised iHEA members (health economist researchers).</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
21	<p>14th May 2019 Koonal Shah Event: City Health Economics Centre Seminar Series Presentation: Generating preference-based values for the EQ-5D-Y to support its use in economic evaluation Location: City University, London UK</p> <p>Koonal discussed the normative and practical challenges involved in valuing health in children, before presenting the methods and findings of two recent EQ-5D-Y valuation studies. The audience comprised health economics staff and students at City University.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
22	<p>15th May 2019 Koonal Shah Event: HEDS Seminar Series</p>

	<p>Presentation: Understanding what aspects of health and quality of life are important to people Location: University of Sheffield, Sheffield UK</p> <p>Koonal presented the methods and emerging findings of a study designed to understand what aspects of health and quality of life people in the UK and Australia consider to be important. The audience comprised health economics staff and students at SchARR, University of Sheffield. The presentation was followed by a meeting with the E-QALY team at SchARR to discuss the comparability of findings across the two studies.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
23	<p>16th May 2019 Bernarda Zamora Event: MedTech Forum 2019 Presentation: Is diagnostic information of value in health care practice? Location: Paris, France</p> <p>The value of diagnostic information "VODI" concept was recently published and European organisations from different chronic and acute disease areas debates the concept and its relevance within the management of their disease. VODI is a holistic framework within Value Driven Health Systems</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
24	<p>18th May 2019 Adrian Towse Event: ISPOR 2019 Presentation: De-risking risk sharing: Enabling payer-pharma interactions and value-based contracting with RWE. Location: ISPOR New Orleans</p> <p>Engaging in value-based contracts continues to be a strategic priority among both payers and biopharmaceutical manufacturers seeking to improve health outcomes while curbing healthcare spending. However, implementation challenges exist to constructing risk-sharing agreements including (a) establishing causality between the biopharmaceutical intervention and relevant outcome (b) transparency and alignment in defining and measuring outcomes (c) enough data infrastructure to execute and track outcomes (d) assessing upfront risk due to uncertainty of real-world performance. This education symposium brought together key stakeholders – from health insurers and manufacturers to real-world data analytics providers – to describe the benefits and barriers of value-based payment models and the promising role of rapid-cycle analytics of real-world data to address these challenges.</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
25	<p>20th May 2019 Lotte Steuten Event: ISPOR 2019 Presentation: The clinical and economic value of genetic sequencing in cancer care: are next generation sequencing (NGS)-based tests clinically useful and cost effective in real world settings? What is necessary to fully realize their value? Location: New Orleans, USA</p> <p>This panel debated the value proposition for the use of NGS-based Dx testing for cancer care using aNSCLC as an example. Lotte moderated the panel and provided an overview of the current landscape of evidence of clinical and cost effectiveness of NGS testing in aNSCLC and posed key questions for the panellists to debate.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
26	<p>20th May 2019 Lotte Steuten Event: ISPOR 2019 Presentation: ISPOR Open-Source Models Special Interest Group: Lies, damned lies and cost-effectiveness</p>

	<p>Location: New Orleans, USA</p> <p>Cost-effectiveness and disease models are often statistically sophisticated and may be seen as opaque by stakeholders [1]. Open-source models (OSM) would encourage greater transparency and facilitate the reuse and updating of the best/most useful models. Per ISPOR-SMDM and EUnetHTA, OSM advanced modelling methods by reducing bias, increasing transparency, improving model access, and allowing for faster access to critical knowledge. With openness and sharing come issues of copyright and access and a need to define how model sharing can be achieved in an equitable manner. The pros and cons of OSMs and the proposed mission of the Open Source Model SIG was debated amongst SIG members.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
27	<p>21st May 2019 Adrian Towse Event: ISPOR 2019 Presentation: Real option value for drugs: is it really an option? Location: New Orleans, USA</p> <p>The ISPOR US Task Force report recommended exploring additional elements of value for inclusion in value assessment of new drugs. One of these was Real Option Value. This panel debated whether and how it could be done, and if this is a good idea.</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
28	<p>21st May 2019 Adrian Towse Event: ISPOR 2019 Presentation: MCDA or weighted CEA based on the QALY? which is the future for HTA decision making? Location: New Orleans, USA</p> <p>This panel discussed whether we should continue to use (and improve) cost-effectiveness analysis as the primary method for technology evaluation or move to (and improve) multi-criteria decision analysis models?</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
29	<p>23rd May 2019 Mireia Jofre-Bonet Event: NHS England/NHS Improvement Economics Career Day Presentation: N/A Location: London, UK (attended remotely via video)</p> <p>This is an annual event hosted by NHS England and NHS Improvement. Mireia was invited to discuss careers in economics,</p> <p>RESEARCH THEME(S): NONE APPLY</p>
30	<p>12-14th June 2019 Bernarda Zamora Event: XXXIX Jornadas de Economía de la Salud (AES Conference) Presentation: Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in Sweden and the UK: The Case of Risperidone Location: Albacete, Spain</p> <p>This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their lifecycle in the UK and Sweden. It concludes that considering the entire lifecycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long run.</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
31	<p>12-14th June 2019 Marina Rodes Sanchez Event: XXXIX Jornadas de Economía de la Salud (AES Conference)</p>

	<p>Presentation: The introduction of pay for performance for specialised care in England Location: Albacete, Spain</p> <p>Prescribed Specialised Services (PSS) Commissioning for Quality and Innovation (CQUIN) schemes were launched in 2013 in England with the aim of improving the quality of specialised care and achieving value for money. During this presentation, Marina described the key features of the schemes and discuss its strengths and weaknesses based on international pay-for-performance literature. The session was organized by Patricia, joint with Laia Maynou (London School of Economics), on behalf of the special interest group on the evaluation of health policies and health care services (EvaluAES).</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
32	<p>12-14th June 2019 Patricia Cubi-Molla Event: XXXIX Jornadas de Economía de la Salud (AES Conference) Presentation: Outcome-based payment schemes: what outcomes do cancer patients value? Location: Albacete, Spain</p> <p>Patricia presented the main results of a project funded by Cancer Research UK with Greater Manchester Health & Social Care Partnership, on making outcome-based payments a reality in the NHS.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
33	<p>12-14th June 2019 Maria Errea Event: XXXIX Jornadas de Economía de la Salud (AES Conference) Presentation: Blood donation in the UK. Are we doing all right or could we do better? Location: Albacete, Spain</p> <p>Blood is collected in the UK through voluntary (not remunerated) human donations. The number of appointments booked with NHS Blood and Transplant (NHSBT) has significantly risen in recent years. However, evidence shows that the number of appointments is greater than the number of final blood donations. Given that there is an urgent need for more blood donors, NHSBT is interested to explore the key factors that are driving potential donors who book an appointment to make a blood donation (or not). The aim of this project is to explore the circumstances and characteristics that lead to a donation, compared to those that do not lead to a donation, amongst people who book an appointment. In this poster presentation, Maria discussed previous research showing that campaigns have an impact on the number of new blood donors and consider data on the number of new donors per day compared with the level of demand in NHSBT.</p> <p>RESEARCH THEME(S): INCENTIVISING QUALITY</p>
34	<p>12-14th June 2019 Maria Errea Event: XXXIX Jornadas de Economía de la Salud (AES Conference) Presentation: Experiencia docente en la organización y gestión de servicios sanitarios Location: Albacete, Spain</p> <p>Maria contributed to a discussion of experiences in delivering a postgraduate course – launched two years ago – for current professionals of the health care system who want to become managers of a health organisation. The presentation was about the experience of teaching to a very particular group of students, most of whom work full time at a hospital or ambulatory health care centre, and about the organisation of the modules.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION-MAKING</p>
35	<p>12-14th June 2019 Marina Rodes-Sanchez Event: XXXIX Jornadas De Economía De La Salud (Aes Conference) Presentation: The introduction of pay for performance for specialised care in England Location: Albacete, Spain</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION-MAKING</p>

36	<p>15th June 2019 Mikel Berdud Event: HTAi 2019 Presentation: Quantifying the Life-cycle Value of Innovative Medicines: The Case of Risperidone Location: Cologne, Germany</p> <p>A presentation of a research by a team of OHE and IHE researchers that estimates the value added by second generation antipsychotics over their lifecycle in the UK and Sweden. The research concludes that considering the entire lifecycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long run.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING; ECONOMICS OF INNOVATION</p>
37	<p>17th June 2019 Lotte Steuten Event: HTAi 2019 Presentation: Health-economic modelling to inform private sector investment in tuberculosis treatment for middle-income countries Location: Cologne, Germany</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
38	<p>17-19th June 2019 Margherita Neri Event: HTAi 2019 Presentation: Adapting HTA and Procurement to tackle antimicrobial resistance Location: Cologne, Germany</p> <p>There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews, and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and recommendations for adapting these systems to respond to the challenges of AMR.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
39	<p>20th June 2019 Mireia Jofre-Bonet Event: Graduating Class for the master's in economics and Business Administration 2019 Presentation: N/A Location: Universitat Autònoma de Barcelona, Barcelona, Spain</p> <p>Mireia presented in front of graduating master's in economics and Business Administration students at her alma mater, Universitat Autònoma de Barcelona.</p> <p>RESEARCH THEME(S): NONE APPLY</p>
40	<p>24th June 2019 Lotte Steuten Event: Roche Meeting Presentation: Value assessment of tumour-agnostic therapies: co-creating market access and HTA roadmaps Location: Brussels, Belgium</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
41	<p>24-25th June 2019 Grace Hampson Event: Challenges in the Adoption of Regenerative Therapies Workshop Presentation: Health Economics (Discussant) Location: Toronto, Canada</p> <p>Discussing presentation on how to evaluate the cost-effectiveness of regenerative medicines, the challenges and experience to date.</p>

	RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING
42	<p>24-25th June 2019 Grace Hampson Event: Challenges in the Adoption of Regenerative Therapies Workshop Presentation: Payment system mechanisms (Discussant) Location: Toronto, Canada</p> <p>Discussing presentation on the available payment mechanisms, whether they are necessary, and how they could be implemented.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
43	<p>28th June 2019 Chris Sampson Event: London Visual Impairment Forum Presentation: N/A Location: Thomas Pocklington Trust, London, UK</p> <p>Chris introduced the use of the EQ-5D in research and decision-making and an overview of our EQ-5D Bolt-ons project.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
44	<p>28th June 2019 Mireia Jofre-Bonet Event: Masterclass for policy makers and the pharma industry Presentation: Introduction to Economic Evaluation Location: Universitat Internacional de Barcelona, Barcelona, Spain</p> <p>Mireia spoke at a recent masterclass, supported by Celgene, on economic evaluation for policy makers and the pharma industry.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY</p>
45	<p>2nd July 2019 Lotte Steuten Event: Lilly GPORWE International Lilly Presentation: The delivery of scientific evidence for the evaluation of medicines throughout their lifecycle Location: Surrey, UK</p> <p>RESEARCH THEME(S): ECONOMICS OF INNOVATION</p>
46	<p>3-5th July 2019 Bernarda Zamora Event: HESG Summer 2019 Presentation: Reconciling ACEA and MCDA: Is There a Way Forward for Measuring Cost-Effectiveness in the U.S. Healthcare Setting Location: Norwich, UK</p> <p>We explore the idea of what could be called a "QALY-anchored" MCDA and compared with a form of Augmented ECA where elements of value are either classified as health or consumption attributes— and ultimately monetised.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
47	<p>13-17th July 2019 Mikel Berdud Event: IHEA world Congress on Health Economics 2019 New Heights in Health Economics Presentation: Quantifying the Life-Cycle Value of Innovative Medicines: The Case of Risperidone and Second-Generation Antipsychotics Location: University of Basel, Basel, Switzerland</p> <p>Mikel's Presentation discussed why the life-cycle value of new medicines should be considered to balance the view that cost per QALY estimates at launch are enough to guide access decisions. Research results presented showed that value added by medicines changes over the life-cycle</p>

	<p>changes in response to the launch of improved and superior presentations, generic competition and new indications. The target audience of this research is composed by policy makers, payers, HTAs (e.g., NICE, SMS), industry and academic researchers interested in the themes of judging value for money and improving decision making and/or Economics of Innovation</p> <p>RESEARCH THEME(S) JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING; ECONOMICS OF INNOVATION</p>
48	<p>13-17th July Olga Rozanova Event: International Health Economics Association (iHEA) World Congress Event IHEA 2019 Presentation: Can price-caps increase prices? Location: Basel, Switzerland</p> <p>Olga constructed a model that studied the effect of price-cap regulation on prices. She presented a rationale for why price-caps may increase equilibrium prices instead of decreasing them,</p> <p>RESEARCH THEME: ECONOMICS OF INNOVATION</p>
49	<p>15th July 2019 Graham Cookson Event: International Health Economics Association (iHEA) World Congress Presentation: International Health Economics Association (iHEA) World Congress Location: Basel, Switzerland</p> <p>Graham presented his paper with his co-author Ioannis Laliotis from the London School of Economics. The paper revisits the relationship between workforce and maternity outcomes in the English NHS to contribute knowledge to an important policy question for which there has been a paucity of research.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
50	<p>16th July 2019 Graham Cookson Event: International Health Economics Association (iHEA) World Congress Presentation: Staffing, Perverse Incentives, and the Determinants of Caesarean Sections in the English NHS Location: Basel, Switzerland</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
51	<p>13-17th July 2019 Koonal Shah Event: International Health Economics Association (iHEA) World Congress Presentation: Novel approaches for valuing health at the end of life Location: Basel, Switzerland</p> <p>Koonal presented as part of an organised session on 'moving beyond conventional economic approaches in palliative and end of life care'. His presentation was discussed by Helen Mason of Glasgow Caledonian University.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
52	<p>23rd August 2019 Mireia Jofre-Bonet Event: Masterclass Participation in Application of Instrumental Variable Methods in Health Economics and Outcomes Research Location: London School of Hygiene and Tropical Medicine (LSHMT), London, UK</p> <p>Mireia participated in a masterclass on Instrumental Variable Methods in Health Economics and Outcomes research and public lecture on Personalised Medicine afterwards.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
53	<p>3-5th September 2019 Apostolos Davillas Event Royal Statistical Society (RSS) Conference</p>

	<p>Presentation: A latent class approach to inequity in health using biomarker data Location Belfast, Ireland</p> <p>This was an honorary/invited presentation/talk that discussed how to develop an empirical approach to analyse, measure, and decompose Inequality of Opportunity (IOp) in health, based on a latent class model. The presentation addressed the limitations that affected earlier work concerning the definition of types- such as partial observability, the ad hoc selection of circumstances, the curse of dimensionality and unobserved type-specific heterogeneity- that may lead to either upwardly or downwardly biased estimates of IOp. They applied the latent class approach to quantify IOp in allostatic load, a composite measure of our biomarker data. Using data from Understanding Society (UKHLS), we find that a latent class model with three unobserved types best fits the data and that these types differ in terms of their observed circumstances. Decomposition analysis shows that about two-thirds of the total inequality in allostatic load can be attributed to the direct and indirect contribution of circumstances.</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
54	<p>18-21st September 2019 David Mott Event: EuroQol Plenary Meeting Presentation: What aspects of health and quality of life are important to people? Existing health and quality of life measures are often considered to be too narrow. Location: Brussels, Belgium,</p> <p>This work explores the aspects of health and quality of life that matter to people, with a view to exploring how a new generic measure might look if built from the 'bottom up'. The methodology and results are of particular interest for studies that set a patient-centred framework. Shah, K.K., Mulhern, B., Cubi-Molla, P., Janssen, B., and Mott, D.J. 2019. "What aspects of health and quality of life are important to people?"</p> <p>EuroQol grant 2016370 Collaborators: Koonal Shah, Louise Longworth (PHMR)Brendan Mulhern (University of Technology Sydney) John Brazier (University of Sheffield) Nancy Devlin (University of Melbourne) Bas Janssen (Erasmus University) Nan Luo (National University of Singapore)</p> <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
55	<p>23-24th September 2019 Mireia Jofre-Bonet Event: IV Expert Programme in Health Policy and the Economics of the Pharmaceutical Sector Presentation: Does the current approach of economic evaluation promote R&D in the pharmaceutical industry? Location: Palma de Mallorca, Spain</p> <p>Mireia was invited to give a talk about economic evaluation and R&D in the pharma industry at the IV Expert Programme in Health Policy and the Economics of the Pharmaceutical Sector in Mallorca, Spain. In Mireia's presentation she discussed the pros and cons of the present HTA/CEA framework for innovation in the pharmaceutical sector in the UK. The panel discussion was based on their experience in different countries.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY</p>
56	<p>23rd September 2019 Bernarda Zamora Event: NIHR London IVD Co-operative Presentation: Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics Location Imperial college London</p> <p>Bernarda gave a Lecture on how to value diagnostics information and the novel elements of value</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
57	<p>26th September Patricia Cubi-Molla</p>

	<p>Event: GSK IMAPRO Meeting Presentation Health valuation, age, and experience Location: Webinar</p> <p>Patricia presented a number of pieces of research she undertook in the past year.</p> <ul style="list-style-type: none"> • A note on the relationship between age and health-related quality of life assessment • Experience-based values: a framework for classifying different types of experience in health valuation research • How experience affects the valuation of EQ-5D profiles: a revision of the UK tariffs using a fixed effects model (working paper, unpublished) <p>RESEARCH THEME(S): MEASURING AND VALUING OUTCOMES</p>
58	<p>3rd October 2019 Graham Cookson Event: LSTHM Presentation A Production Function for Maternity Services in the English NHS Location: London</p> <p>This paper analyses the role of medical and non-medical staff in the production of maternity services in the English NHS. Using hospital panel data (2004-2012) and estimating flexible production functions using system GMM estimators, we explore the output contribution of maternity services labour inputs. The results suggest that consultants and doctors have the highest marginal productivities while the productivity of support workers is insignificantly different from zero. Moreover, there is evidence for some degree of complementarity between midwives, support workers and consultants. Moreover, midwives could replace doctors and doctors could replace consultants in the production of maternity services.</p> <p>RESEARCH THEMES): MEASURING AND VALUING OUTCOMES</p>
59	<p>16th October 2019 Martina Garau Event: Orphan Drugs and Rare Diseases conference Presentation: MoCA early dialogue between payers and manufacturers: An Opportunity to Improve Decision Making for Orphan Drugs in Europe? Location: London</p> <p>Orphan drugs inherently face a number of challenges in their development and value assessment. In my presentation, I describe the Mechanism of Coordinated Access (MoCA) initiative and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.</p> <p>RESEARCH THEME(S): JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
60	<p>4-5 November 2019 Mireia Jofre Bonet Event: ISPOR Europe 2019: Presentation: Is indication-based pricing feasible and/or beneficial for society? Location: Copenhagen</p> <p>Chair: Mireia Jofre-Bonet OHE Participants: Andrew Briggs LSHTM Adrian Towse OHE Francis ARYCKS, National Institute Health & Disability Insurance, Belgium Mireia introduced the subject of whether the IBP is beneficial to society or not, with a few PROS and CONS and lead the discussion afterwards.</p> <p>RESEARCH THEME(S) ECONOMICS OF INNOVATION</p>
61	<p>4th November 2019 Patricia Cubi-Molla</p>

	<p>Event: ISPOR Europe 2019 Poster session: Making outcome-based payment a reality in the national health service for England Location: Copenhagen, Denmark</p> <p>This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes</p> <p>RESEARCH THEME(S) MEASURING AND VALUING OUTCOMES; JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
62	<p>5th November 2019 Amanda Cole Event: ISPOR Europe 2019 Poster: Should drug prices differ by indication? Results of a consultation. Location: Copenhagen, Denmark</p> <p>We report the results of a consultation where we sought the insight of different stakeholders (industry, payers, regulators, and academics) from across different European countries, on the relative merits of IBP and issues around its implementation. Funded by AstraZeneca (832)</p> <p>RESEARCH THEME(S) JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING; INCENTIVISING QUALITY</p>
63	<p>5th November 2019 Chris Sampson Event: ISPOR Europe 2019 Poster: The impact of a digital sleep-improvement program on health care costs Location: Copenhagen, Denmark</p> <p>We report on an interim evaluation of population rollout of Sleepio, estimating the change in primary care costs. Using an interrupted time series analysis, we show a small shift to a downward trend in primary care costs. Oxford AHSN (823)</p> <p>RESEARCH THEME(S) JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
64	<p>5th November 2019 Chris Sampson Event: ISPOR Europe 2019 Presentation: Development of EQ-5D-5L bolt-ons for cognition and vision Location: Copenhagen, Denmark</p> <p>We report on a series of qualitative focus groups and interviews to identify the domains and terminology for two EQ-5D bolt-ons. The findings inform qualitative and quantitative testing of candidate bolt-on descriptors.</p> <p>Research theme(s) Measuring and valuing outcomes 14th November 2019 Patricia Cubi-Molla Event: City, University of London Presentation Health valuations, age, and experience, Module: ECM163 Economic Evaluation Location: London, UK</p> <p>Patricia gave a lecture/seminar to students of MSc Economic Evaluation in Health care and MSc Health Economics. The slides put together material from a number of pieces of research I undertook last year:</p> <ul style="list-style-type: none"> •A note on the relationship between age and health-related quality of life assessment

	<ul style="list-style-type: none"> •Experience-based values: a framework for classifying different types of experience in health valuation research •How experience affects the valuation of EQ-5D profiles: a revision of the UK tariffs using a fixed effects model (working paper, unpublished) <p>RESEARCH THEME(S) MEASURING AND VALUING OUTCOMES</p>
65	<p>19th November 2019 Simon Brassel Event: LSE Lunch Time Career Event Presentation: Careers in Health Insight Programme: Medical devices to Research Location: London, London School of Economics</p> <p>A presentation and Q&A session to students with an interest in a career in health economics/health policy.</p> <p>RESEARCH THEME(S) - NOT APPLICABLE</p>
66	<p>21 November 2019 Mireia Jofre-Bonet Event: Stroke Foundation Presentation: Attended Steering Group meeting for the SUPERB trial: Location: member of the Steering Group for this grant on supporting people after stroke using buddies. It is funded by the STROKE foundation. Yes, you can publish it.</p> <p>The trial is called: Adjustment with aphasia after stroke: Supporting wellbeing through PEer Befriending (SUPERB), funded by the Stroke Association.</p> <p>RESEARCH THEME: INCENTIVISING QUALITY</p>
67	<p>26-27th November Mireia Jofre-Bonet Event: The King's Fund annual conference 2019: delivering population health Presentation: Improving stroke prevention through place-based care</p> <p>Mireia was invited to the VIP lunch on the 27th of November in which we discussed: Improving stroke prevention through place-based care</p> <p>RESEARCH THEME: INCENTIVISING QUALITY</p>
68	<p>6th December 2019 Graham Cookson Event: City University Presentation: Economics of Maternity Services Location: London</p> <p>Graham gave a presentation at City Health Economics Centre, he first presented trends in maternity services in the English NHS before presenting research on two topics: (i) the role of staffing levels and skill mix on provider efficiency, and (ii) the impact of staffing and skill mix on the rate of Caesarean sections</p> <p>Leverhulme Trust Research Leadership Award I Laliotis (City) B Zamora (OHE) M Neri (OHE)</p> <p>RESEARCH THEME(S): INCENTIVISING QUALITY</p>
70	<p>5th December 2019 Chris Sampson Event: University College London Presentation: A new conceptual framework for pricing medicines: beyond cost-effectiveness thresholds. A critique and consideration from the UK perspective Location: London</p> <p>My presentation provided a critical response to the threshold proposed by Mike Paulden for the identification of cost-effectiveness thresholds. The framework has been used in Canada.</p>

	RESEARCH THEME(S): INCENTIVISING QUALITY; JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING
71	<p>9th December 2019 Mireia Jofre-Bonet Event: Executive MSc in Health Economics, Policy and Management Presentation: Are user fees in health care always evil? Perceived quality of family planning, maternal and child health services in Egypt' (Amira El-Shal, Patricia Cubí-Mollà, Mireia Jofre-Bonet) Location: London Mireia Jofre-Bonet is presenting this joint paper as a lecture on methods for the students at the London School of Economics and Political Science (18 December)</p>
72	<p>9th December 2019 Mireia Jofre-Bonet Event: Executive MSc in Health Economics, Policy and Management Presentation: Are user fees in health care always evil? Perceived quality of family planning, maternal and child health services in Egypt' (Amira El-Shal, Patricia Cubí-Mollà, Mireia Jofre-Bonet) Location: London</p> <p>Mireia Jofre-Bonet is presenting this joint paper as a lecture on methods for the students at the London School of Economics and Political Science (18 December) Research theme(s) RESEARCH THEME(S): INCENTIVISING QUALITY; JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
73	<p>11th December 2019 Adrian Towse Event: London School of Hygiene and Tropical Medicine - Internal event organised by the CHIL Presentation "Opportunity Cost thresholds: new empirical approaches, methods and applications". Location: London</p> <p>Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results from a UK feasibility study This project presents additional empirical evidence of the relationship between health outcomes and health expenditures in England and discussed the policy implications RESEARCH THEME(S): INCENTIVISING QUALITY; JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>
74	<p>20th December 2019 Mireia Jofre-Bonet Event: A seminar at the 2nd Winter Workshop of the Catalan Economic Society (SEC) of the Institut d'Estudis Catalans in Barcelona (20 December) Location: Barcelona, Spain</p> <p>Presentation: Mireia Jofre-Bonet is presenting this joint paper "Are user fees in health care always evil? Perceived quality of family planning, maternal and child health services in Egypt" (Amira El-Shal, Patricia Cubí-Mollà, Mireia Jofre-Bonet) RESEARCH THEME(S): INCENTIVISING QUALITY; JUDGING VALUE FOR MONEY AND IMPROVING DECISION MAKING</p>

4.6.2 Advisory roles held by OHE staff members

The number of advisory roles of OHE staff members has continued growing and reflects the good standing of OHE members in terms of impacting in policy and being able to judge valuable research. Having impact and helping steer health policy and decision making in health economics is an essential OHE charitable object.

OHE staff membership of advisory panels, boards and committees

1. NICE: Public Health Guidelines Standing Committee – Grace Hampson
2. NICE: Member of the Expert Advisers Panel for the Centre for Guidelines – Mireia Jofre-Bonet
3. iHEA: Special interest group on the economics of obesity – Grace Hampson
5. iHEA: Member of the 'health systems' efficiency' interest group – Margherita Neri
6. iHEA: Programme Chair Scientific Committee on Production of Health, Health Behaviours & Policy – Apostolos Davillas
7. ISPOR: Value Frameworks Special Task Force – Adrian Towse
8. ISPOR: Board of Directors Past President – Adrian Towse
9. ISPOR: Oncology Special Interest Group Member – Graham Cookson
10. ISPOR: Rare Disease Special Interest Group Member – Graham Cookson
11. ISPOR: Statistical Methods in Health Economics and Outcomes Research Special Interest Group Member – Graham Cookson
15. ISPOR: Member of the 'Value of Information' Task Force – Lotte Steuten
16. ISPOR: Health Preference Research Group Member – David Mott
16. EvaluAES (supported by the Spanish Health Economic Association): Co-ordinator of special interest group on the evaluation of health policies and health care services – Patricia Cubí-Mollá
17. EvaluAES (supported by the Spanish Health Economic Association): Member of special interest group on the evaluation of health policies and health care services – Maria Errea
18. EuroQol Group: Executive Committee – Koonal Shah
19. NIHR: Steering Committee Member for NIHR/HS&DR Project No. 8/17/1934 – Graham Cookson
20. NIHR – Member of a Study Steering Committee (SSC) for the LOGIC (Longitudinal Outcomes of Gender Identity in Children) project – Mireia Jofre-Bonet
21. MRC: Advisory group for Extending the QALY project – Koonal Shah
22. UK Pharmacogenetics & Stratified Medicine Network: Member – Bernarda Zamora
23. Health Foundation: Steering Committee Member for NHS Workforce Retention Project – Graham Cookson
24. Scientific Experts and Methodologists Group (SEM) Delphi Panel Member of the IMPACT-HTA (WP7) project "Improved methods and actionable tools for enhancing HTA" – Martina Garau
25. Editorial Board Member, *Applied Health Economics and Health Policy Journal* – Lotte Steuten
26. Co-Creation Panel Pricing and Reimb Tumor-Agnostics Therapies: Moderator – Lotte Steuten
27. *PharmacoEconomics*: Editorial Board Member – Chris Skedgel
28. *PharmacoEconomics* – Open: Editorial Board Member – Chris Sampson
29. International Health Economics Association Scientific Committee - Program Chair – Production of Health-Health Behaviours & Policy-Renewed for the 2019-2021 - Apostolos Davillas
30. Member of the Steering Group of the Early Diagnosis Research Alliance – Bernarda Zamora

Visiting positions for OHE staff

1. School of Health and Related Research, University of Sheffield –Honorary Research Fellow – Koonal Shah
2. London School of Economics –Visiting Professor –Adrian Towse
3. Nuffield Department of Population Health, University of Oxford –Senior Visiting Fellow –Adrian Towse
4. Oxford University Hospitals NHS Trust –Honorary Health Economist –Amanda Cole
5. Oxford University Hospitals NHS Trust –Honorary Health Economist –Chris Sampson
6. Public University of Navarra and The Navarra's Health System –Invited Lecturer on Management and Organization of Health Care Services –Maria Errea.
7. Public University of Navarra –Visiting Researcher –Mikel Berdud
8. University of Surrey –Visiting Professor –Graham Cookson
9. Science Policy Research Unit, University of Sussex –Associate Faculty Member –Grace Hampson
10. City, University of London –Honorary Visiting Professor–Lotte Steuten
11. City, University of London –Honorary Visiting Professor –Graham Cookson

12. City, University of London –Professor, Department of Economics –Mireia Jofre-Bonet
13. City, University of London –Honorary Senior Research Fellow–Patricia Cubí-Mollá
14. University of York –Research Affiliate: Health, Econometrics and Data Group (HEDG) –Apostolos Davillas
15. University of Essex –Research Fellow: Institute for social and Economics Research –Apostolos Davillas
16. Fred Hutch Cancer Research Center, University of Washington –Affiliate Investigator –Lotte Steuten
17. University of East Anglia –Honorary Senior Fellow –Chris Skedgel
18. University of York, Health -Econometrics and Data Group (HEDG) -Research Affiliate –Apostolos Davillas
19. University of Essex -Institute for social and Economics Research -Research Associate – Apostolos Davillas

4.6.3 Examples of OHE’s impact

In 2019, OHE’s work has continued to have a remarkable impact. Below, we list those we have a record of:

Citations of OHE research by decision-makers, policy influencers and the media

- **OECD ‘Health at a glance 2019: OECD Indicators’** cites: Devlin, N. & Lorgelly, P. & Herdman, M., 2019. "Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA," Research Papers 002094, Office of Health Economics.
- The OHE Research Paper 'Making Outcome-Based Payment a Reality in the NHS' was cited in a **press release by Cancer Research UK**. It was also cited by commentators and media outlets such as **Pharmatimes, Pharmafield, PMLive, The Pharma Letter, Royal College of Nursing, Health Innovation Manchester, and Medscape**. The Medscape article included a quote from NICE welcoming the publication of the paper.
- **El Global** (leading pharmaceutical newspaper in Spain), policy section, discusses the OHE Research Paper 'Making Outcome-Based Payment a Reality in the NHS'. (August 2019) <https://elglobal.es/politica/reino-unido-estudia-como-sistematizar-el-pago-por-resultados-en-oncologia-mi2208086/>
- OHE’s Brexit analysis was cited in the **Government impact assessment** on the implications of setting up the MHRA as a standalone UK regulator. As a result, it was referenced in articles in **The Times** and **Politico**. OHE’s report on Brexit was also cited in an article on **PMLive**.
- The business and technology news website **xconomy.com** featured an article about the OHE and ICER white paper on models for pharmaceutical rebates. An article on the white paper was also published in **The Pharma Letter**.
- The **Center for Global Development** recently published a critique of the World Health Organization’s technical report on cancer drug pricing. The critique was co-authored by Adrian Towse. **Politico Europe** named both Adrian and OHE in their health care briefing on the topic.
- NICE expressed interest in OHE’s work on valuing health in children, and invited Koonal Shah to present at a NICE Technical Briefing in March 2019. The event was attended by over 40 analysts, and members of NICE’s Science and Policy Research team organised internal follow-up discussions to reflect on the issues raised and further meetings with OHE to take the research agenda forward. See here for an **OHE blog** on this presentation.

Impact on the research of others

In February 2019, a Senior Economist at the Department of Health and Social Care received a request for information on NHS expenditure on branded medicines from a professor of law at Suffolk

University Law School in the US. He responded by referring the requestor to OHE's research on NHS expenditure.

In February, Fabia Gansen of the University of Bremen got in touch with Koonal Shah to advise him that she is working on a programme of research that builds on and is inspired by OHE's research on 'personal utility functions'.

Advice sought from OHE

There are numerous cases of advice sought from OHE, as an example, In March 2019, Graham Cookson and Koonal Shah provided a small amount of pro bono advice to policy advisers at the Treasury (following a request for advice/information) regarding the value of QALYs.

5 Research Plans for 2020

5.1 General Research Strategy

As explained above, at the end of last year, researchers at OHE identified 5 research topics for each of the four research themes which they thought would generate most research interest in the year 2020 and beyond. The selected top 5 topics per theme were to be sent to key researchers and stakeholders for an indicative vote for the one topic under each theme that they believe was going to be most salient in 2020. This strategic exercise, which we called **Top 20 Research Topics for 2020**, had the objective of getting a sense of what key individuals believed were going to be the top-priority areas of knowledge in the near future. This information was presented to the **Research Committee** in January 2020, which provided very valuable feedback on the interest and ultimate relevance of some of these themes to the team.

OHE's **primary** research objective for 2020 was and still is to significantly, but sustainably, grow our external research funding by adopting the following strategies:

1. **Future Leaders:** to develop future research leaders within OHE and increase the number of staff acting at Principal Investigator level to share the burden of increasing our research funding more broadly. We are investing in supporting the next generation of research leaders within our organisation, by increasing their profile, establishing more structured/periodic communication channels to stimulate and catalyse activity, while offering an enhanced research environment
2. **Alignment:** we are developing a more efficient and systematic approach to identify, select, and respond to funding calls. The intention is to be able to better align OHE's proposals to funders' *sought-after* topics. This should enable OHE to balance funded research across research themes
3. **Efficiency:** we want to improve the time we spend on writing applications and to increase the average length and value of research grants we apply for. As part of this effort, we intend to systematically explore potential patterns in successful and failed grant applications to increase our success rate

The **secondary** research objective is to continue to improve the research environment of OHE, and we have several strategies to achieve this goal:

1. Launch an **OHE Annual Conference**
2. Expand the number of **OHE Visiting Fellows** (including Visiting Policy Fellows) and deepen these and existing relationships

3. **Enhance the training opportunities and programmes** (we have started a OHE-MSc in Health Economics Fellowship at City and are aiming to find funding for a PhD in the Micro-economics and Econometrics of the Pharmaceutical Industry)
4. Define and develop our partnership with City, University of London, as well as other universities

Internally, we planned to develop our research strategy in the following manner:

- Each theme to hold a **theme quarterly meeting** chaired by the theme lead and attended by OHE staff interested in that theme. Potential funding opportunities, research ideas and activities to be discussed and agreed upon
- Theme leads to meet with the Head of Research **quarterly** to discuss the development of research topics and research issues of general interest that are relevant to all themes
- We are considering starting a **Lunch-time Journal Club** to debate recent articles and/or novel ideas in health economics. One possibility is to draw from our colleague Chris Sampson's blog **'THE ACADEMIC HEALTH ECONOMISTS' BLOG'**
- We are considering whether to create a **Specialist Digital Seminal Papers' Library** on particular topics in health economics. This library would be both a tool to do research but also a means for staff to learn about especial health economics research topics, independently
- We are planning to re-visit the possibility to **improve direct access to Digital Libraries**, to avoid relying on individual access to universities with which individual staff are affiliated
- We are continuing to **develop and systematise the information on forthcoming funding calls** – e.g. updating our file based on main funders (MRC, NIHR, Gates Foundation) and/or coordinating with the research office of the Health Sciences department of City, University of London
- Explore, agree, and put in place a **OHE open access policy** for OHE research output. At the suggestion of our colleague, Chris Sampson, in 2020 opportunities for OHE to commit to more transparent research practices to be investigated as well as the potential value to OHE of committing to initiatives such as open access publication and open data, along with considering the development of repositories and internal mandates and policies to support these.

5.2 Research Plans by Theme and Presentation by Leads

As objectives for all themes in 2020, OHE agreed that:

- each theme aims to submit at least **one research grant** relating to their top research topics
- each theme to organise at least one **Lunchtime Seminar** to establish contact and explore collaborations with experts that can be relevant for joint grant submissions for one of the 2020 topics for each research theme or other research projects. While the content of the presentation may be different to the 2020 topic, this should enable the team to explore common topic interests
- each theme to organise a panel session at the **OHE 2020 Conference** related to one of their 2020 top topics

- theme leads aim to blog on their themes' research hot topics. The purpose is to use the OHE's blog strategically to 'make noise' and attract attention to the topic, generating potential new research collaborations

In the following section, we present the updated research plans for 2020 by Theme. Additionally, each theme leader to lead a short discussion of their research goals in the next year.

Judging Value for Money and Improving Decision-Making (Martina Garau)

Main topic

The role of the cost effectiveness threshold in HTA decision making to implement value-based pricing seems to be recognised in an increasing, QALY-driven, number of countries (both high-and middle-income). For example, there is a proposal in Canada to introduce an explicit threshold to set prices at product launch. Traditionally, OHE work on thresholds has been commissioned by UK funders and has helped informed the academic and policy debate in the UK.

Giving the growing importance in other contexts, we would value suggestions from the Committee on how to explore new sources of funding outside the UK around the topic of cost effectiveness thresholds and their role in funding decisions.

Other key topics for 2020

- Interest in multi-attribute frameworks in the US and other geographies is expected to continue. Related key areas identified as important to explore are the development of robust methods for aggregation (going beyond a simple definition of a list of elements of value) and the generation of evidence on societal and patient preferences to inform decision-making.
- Continuing exploring the issues related to the assessment and separation of value of interventions to use jointly (e.g. combination therapies, and companion diagnostic and treatment).

The Research Away Day 2019 was a good opportunity to identify the key hot topics that we might want to explore in 2020. Feedback on the five selected is very welcome. The list that emerged is:

HOT TOPICS IN 2020:

Judging value for money / structured decision making	
1	Developing good practice in HTA: What is the optimal model for reimbursement decision-making in different contexts?
2	Cost-effectiveness and treatment pathways: How can evidence of value be incorporated into clinical decision-making?
3	Understanding opportunity costs: How can we reconcile expanded concepts of value and displacement?
4	Real-world evidence and data systems: Can digital systems support decision-making?
5	Multi-sectoral resource allocation: How should resource allocation be managed beyond health and health care?

Economics of Innovation (Mikel Berdud)

Main objective for 2020

Given the sources of income of this theme, it appears to be responding to private for-profit funders' demand. Thus, the stream of consulting work is very healthy but there might be a need to rebalance towards research. The theme lead indicated that ideally the number of peer review publications and independent research ought to increase to achieve this. To achieve this objective in 2020 it is crucial to set a research grants application strategy as well as to work in external research collaborations, in particular, with academics and universities, but also with other research institutions (e.g., consultancies, think-tanks, charities)

Main topic

Main topics

In terms of being proactive, the team identified two main research areas of interest for this theme:

First, subjects related to:

- Price transparency
- Indication based pricing
- Outcomes based pricing
- Combination therapy pricing
- Paying and pricing cures
- Value-based pricing of cancer drugs
- Global health and NTD
- Alternative models of rebates
- Regulation and incentives for OMPs
- Competition and regulation: tendering
- Open innovation
- Adaptive pathways
- Real-world evidence
- Health systems barriers

Second, the team perceived that the market itself demands research in the following subjects:

- Indication based pricing
- Price transparency
- Combination therapy pricing
- Paying and pricing cures
- Competition and regulation: tendering
- Regulation and incentives for OMPs
- Regulation and incentives for AMR
- Adaptive pathways
- Real-world evidence
- Life-cycle value of innovation

Although there is a large overlap, OHE researchers interested in this research theme want to target funded research contracts that satisfy the members' intellectual curiosity, i.e. those subjects that are not so much sought-after by the market. To do so, the strategy must be to increase funded research

contracts from private for-profit funders; to attract/win funding from public, non-profit, charities and work on partnerships with Universities, research institutes, and thinktanks/consultancies that are interested in those topics. To apply to research grants by non-profit funders; and promote and chase commercial research contracts for-profit.

A new staff member specialised in Industrial Organisation with a PhD degree and several post-doc positions in the field of the economics of innovation and pharmaceutical R&D to join the OHE in June 2020. The incorporation of a new OHE team member with such theme-relevant background should greatly aid the achievement of the 2020 objectives.

The main challenge for this theme in the short and medium term are the environmental constraints such as Brexit and the pending IRO status, which pose an extra test on the expansion and progression of funding opportunities.

In any case, the main goals of this theme are to expand and diversify the sources of income; to get more funded research projects; to work on collaborations to reach out to more potential funders; and, to target more peer reviewed journal publications of research outputs.

Selection of hot topics in 2020:

The lead joint with the OHE team worked in the identification and selection of the most relevant and intellectually interesting topics within the theme of the economics of innovation. The selection process was based on balancing what the market demand with what team members are interested on – the overlap of the two sets identified and listed above. Feedback on the five selected is very welcome. The list that emerged is:

HOT TOPICS IN 2020

Economics of innovation	
1	Outcomes-Based 'Contracting': How can Outcome-Based Contracting accelerate market access and manage payers' uncertainty?
2	Innovative pricing: How can innovative pricing incentivise Pharmaceutical R&D?
3	Innovation in the Pharmaceutical Sector: What is the societal benefit of pharmaceutical innovation and how to measure it appropriately?
4	Pharmaceutical R&D: Is there a role for patent pools and public-private partnerships?
5	Price Transparency: Who benefits from and what are the negative effects of price transparency? Can confidential prices remain whilst delivering benefits of price transparency?

Incentivising Quality (Margherita Neri)

- At the 2019 OHE Research Away Day the team agreed that the theme name requires a revision. The name 'Incentivising Quality' focuses too narrowly on research around incentives and reimbursement schemes, and this does not appropriately reflect what this theme aims to capture in terms of OHE interest and current expertise. This action is in progress and we are expecting to be able to introduce a new, more comprehensive name in Q1 of 2020. Following multiple rounds of discussion and feedback, the most popular name candidate is currently 'Policy, organisation and incentives in health systems. A renovated and more suitable theme title is expected to bring greater opportunities for internal cohesion and easier identification of our expertise from external funders.
- Other organisations undertaking consultancy/ research work on health systems appear to have been engaged in projects for the UK Department of Health and Social Care and NHS England. OHE could also try to explore opportunities with these clients.

- The core research pipeline for this theme looks 'healthy'. It includes a fair number of projects aiming to develop the necessary expertise to apply to externally funded work, as well as to publish in peer-reviewed journals.
- Several research proposals were submitted to prestigious funders in 2019 (e.g. the Health Foundation, NIHR, MRC) but were rejected. The topic areas of these applications concerned inequality of access to cancer screening, adolescent mental health in developing countries and relationship between birth mode/setting and long-term outcomes. OHE needs to identify the reasons for these failures and design effective strategies to resubmit these proposals in 2020.

Main objectives for 2020:

- To obtain another large multi-year research grant. This should help accumulating a stable source of income over the forthcoming years and fill the gap that should be left by the NIHR funded PSS-CQUIN project
- To develop new or capitalise on existing relationships with other health economics research centres to build opportunities for collaborations and joint grant application submissions. Existing networks include the Private Health Information Network and the Division of Health Service Delivery within the School of Population Health at NYU Langone.
- To strategically promote the use of the core research activities, with the aim to develop research ideas and internal knowledge that can be used to obtain external funding.
- The list that emerged from the theme brainstorming for the 5 hot research topics in this area are:

HOT TOPICS IN 2020:

Incentivising Quality	
1	Workforce retention: How can the NHS effectively recruit and retain mental health nurses?
2	Inequality: How to reduce income-related inequality in access to cancer screening and in health outcomes?
3	Brexit: What are the effects of Brexit for health care professional retention?
4	Allocative Efficiency: What is the right weight we should give to prevention, primary care, hospital care and long-term care to maximize health-related outcomes?
5	Financial and non-financial incentives for providers: How could bettering work conditions of nurses improve retention in the NHS? What are the pull mechanisms for nurses by private health care providers?

Measuring and valuing outcomes (Patricia Cubí-Mollá)

- In 2019, a total of 15 on-going projects are labelled under the Measuring and Valuing Outcomes group, 13 of which are funded research and two correspond to consulting. With a few exceptions, the projects have low budgets and six of them are linked to the EuroQol Foundation. Core research projects on the theme are very scarce, and all of them focus on completing papers rather than as a source of pump-priming for more challenging projects.
- One of the main challenges is to incentivise the collaboration between new OHE staff to create new research pathways and establish the extant ones. The theme-related meeting, and follow-up conversations have provided a wider scope of the potential research topics, and synergies in the group. There is discussion on new research projects, such as process utilities or incorporation of patient preferences to HTA, and other topics which were already developed (as experience-based values) are now being resurrected and a project should be submitted for core research.
- Currently Mike Herdman is the only member of the OHE staff who is a member of the EuroQol group. A challenge is to create a stronger link between OHE and the EuroQol group, with the

potential application for membership of those who are undertaking research closer to the group (Chris Sampson, David Mott, Bernarda Zamora, Patricia Cubi-Molla).

OPPORTUNITIES:

- The new OHE masterclass Outcomes-based contracting can be used as a platform to increase the profile of the theme group (e.g. outcome-related projects that can be delivered by OHE) among the relevant stakeholders.
- Recent recruitment has brought experts (Chris Skedgel, Eleanor Bell, Nadine Henderson) with different levels of experience who can help broaden the scope of topics covered by the theme.
- The brainstorm exercise during the Research Away Day about hot topics identified lines of research that can be approached from more than one group. For instance, value-based pricing, or the incorporation of PROMs into HTA decision-making. This presents OHE with an opportunity to build up a strong-based line of research which could put OHE as a key reference for the topic

GOALS FOR 2020:

- To keep on promoting group engagement and building capacity. Facilitate conversations and share knowledge of each of the theme-related experts in OHE.
- To suggest at least one speaker for an OHE lunchtime seminar.
- To propose and organise courses and/or issue panels on outcomes-related topics at conferences such as ISPOR, seeking collaboration with external contacts

The list that emerged from the theme brainstorming for the 5 hot research topics in this area are:

HOT TOPICS IN 2020:

Measuring and valuing outcomes	
1	PROs and patient-centred care: What are the opportunities and challenges?
2	Outcomes based pricing based on PROs: Is it feasible? Is it desirable?
3	Incorporating patients' preferences into HTA: Should it be done? If so, how?
4	Challenges of using PROs: What are the challenges of using PROs in challenging populations (e.g. young, rare diseases)?
5	Patient experience: How does patient experience affect the measurement and valuation of health outcomes? What is the potential impact?

6 Update on status of Independent Research Organisation Application

The status of Independent Research Organisation is needed by OHE to be allowed to apply to funding calls of UK research councils (Medical Research Council - MRC, and Economic and Social Research Council - ESRC) and other bodies.

We submitted the application to the **UK Research and Innovation Office** at the end of August 2019. We were assured that the application has 'gone through' the **ESRC** and posteriorly referred to the **Department for Business, Energy and Industrial Strategy** to review.

At the end of 2019 we were waiting for a response that materialised in February 2020 with the much sought award of the IRO status OHE.

7 Concluding Remarks

The year 2019 was a critical point in the history of OHE. The Executive and Senior management teams had changed almost entirely– with Adrian Towse passing over the directorship, the political environment changing radically, and new challenges faced by the health care system and by the pharmaceutical sector.

OHE 's survival as a well-regarded research centre relied (and still does) on OHE maintaining its strong reputation for producing high quality research in health economics, independent from external pressures or influences. Revenues from our research consultancy help support OHE's research programme and the attainment of its charitable objects.

To survive in this new environment OHE aims to increase its funding base. Thus, OHE current strategy includes drawing from a more diverse than usual array of funding sources. The goal is to raise more research grants and win more research consultancy projects but, also, to invest in new initiatives that are scalable but do not necessarily involve proportional expansions of manpower (such as our proposed Masterclasses series, etc).

Investing time and effort in seeking funds for strategically critical research topics while producing research of high quality and navigating the evolving socio-economic environment is paramount for OHE to thrive. This is the reason the input of the **Research Committee** is now more critical than ever.



About us

Founded in 1962 by the Association of the British Pharmaceutical Society, the Office of Health Economics (OHE) is not only the world's oldest health economics research group, but also one of the most prestigious and influential.

OHE provides market-leading insights and in-depth analyses into health economics & health policy. Our pioneering work informs health care and pharmaceutical decision-making across the globe, enabling clients to think differently and to find alternative solutions to the industry's most complex problems.

Our mission is to guide and inform the healthcare industry through today's era of unprecedented change and evolution. We are dedicated to helping policy makers and the pharmaceutical industry make better decisions that ultimately benefit patients, the industry and society as a whole.

OHE. For better healthcare decisions.

Areas of expertise

- Evaluation of health care policy
- The economics of health care systems
- Health technology assessment (HTA) methodology and approaches
- HTA's impact on decision making, health care spending and the delivery of care
- Pricing and reimbursement for biologics and pharmaceuticals, including value-based pricing, risk sharing and biosimilars market competition
- The costs of treating, or failing to treat, specific diseases and conditions
- Drivers of, and incentives for, the uptake of pharmaceuticals and prescription medicines
- Competition and incentives for improving the quality and efficiency of health care
- Incentives, disincentives, regulation and the costs of R&D for pharmaceuticals and innovation in medicine
- Capturing preferences using patient-reported outcomes measures (PROMs) and time trade-off (TTO) methodology
- Roles of the private and charity sectors in health care and research
- Health and health care statistics